You are on page 1of 45

Obstetrics and Gynecology - 2009

Editor-in-Chief
Rogerio A. Lobo, M.D.
Professor of Obstetrics & Gynecology,
College of Physicians and Surgeons
of Columbia University, New York, NY
Chapter 9:
Obstetric
Complications
Errol R. Norwitz, MD, PhD
Men-Jean Lee, MD

Contents

1. Cervical Insufficiency

2. Preterm Labor

3. Post-term Pregnancy

4. Hypertensive Disorders of Pregnancy

5. Intrauterine Fetal Demise

6. Intrauterine Growth Restriction

7. Multiple Pregnancy

8. Premature Rupture of Membranes

9. Antepartum Hemorrhage

10. References

11. Questions

CHAPTER 9: OBSTETRIC COMPLICATIONS 217


1. Cervical Insufficiency

Cervical insufficiency (also known as cervical incom-


petence) is defined as a functional weakness of the
Management

cervix resulting in a failure to carry a pregnancy to Cervical cerclage has become the mainstay for the
term.1, 2 It complicates 0.1%-2% of all pregnancies, management of cervical insufficiency. If the prior
and is estimated to be responsible for 15% of deliver- preterm delivery was the result of preterm labor (docu-
ies between 16 and 28 weeks of gestation.3-5 The clas- mented active contractions) and not cervical insuffi-
sic presentation is that of painless cervical dilatation ciency, cerclage placement is not indicated.2
and shortening without evidence of uterine
contractions.6 Types of Cerclage
Prophylactic (elective) cervical cerclage is indicated
in women with a history of prior pregnancy loss and/or
preterm delivery with a history consistent with cervical
Etiology

Some risk factors for cervical insufficiency are insufficiency, because the probability of recurrence of
described (Table 1), but most patients have no risk cervical insufficiency in a subsequent pregnancy is
factors.1, 2 15%-30%.1, 7, 8 Prophylactic cervical cerclage is placed
most commonly at 13-16 weeks of gestation, at which
The exact etiology of cervical insufficiency has not time the complication rate is low (<1%).2 Prophylactic
been elucidated.6 cerclage for diethylstilbestrol (DES) exposure (when
the patient was exposed in utero to DES taken by her
mother) alone remains controversial. Most clinicians
believe that a history of in utero DES exposure per se
Diagnosis

Cervical insufficiency is a clinical diagnosis charac- (without a history of prior pregnancy loss) is not an
terized by acute, painless dilatation of the cervix, usu- indication for prophylactic cerclage placement. Simi-
ally in the mid-trimester (generally between 16-24 larly, elective cerclage has not been shown to be benefi-
weeks), culminating in fetal membrane prolapse cial in women with multiple pregnancies without a
and/or premature rupture of the membranes (PROM) prior history of cervical insufficiency.9-12
with resultant preterm and often previable delivery.
The primary indication for emergent (salvage, res-
cue) cervical cerclage is premature effacement and/or
dilatation of the cervix in the absence of labor prior to
28 weeks gestation. It is associated with a less than
50% success rate. Poor prognostic features include cer-
vical dilatation >4 cm and prolapsed membranes. In

Table 1

Risk Factors for Cervical Insufficiency

Congenital Acquired

Müllerian abnormalities Cervical trauma (prior surgical or


(congenital cervical hypoplasia or aplasia) obstetric trauma)

In utero diethylstilbestrol (DES) exposure Connective tissue abnormalities


(Ehlers-Danlos syndrome)

218 OBSTETRICS AND GYNECOLOGY—2009


general, most practitioners do not place an emergent quent studies were unable to confirm these observa-
cerclage after fetal viability is reached (after 24 tions. In a recent multicenter randomized clinical trial,
weeks), due to the inherent high risk of causing an 47,123 women with singleton pregnancies were
iatrogenic rupture of fetal membranes and accelerat- screened by transvaginal cervical length measure-
ing the preterm delivery. An alternative plan of man- ments at 22-24 weeks gestation. Cervical length was
agement in these pregnancies is bed rest for the dura- shortened (≤15 mm) in 470 women. Of these, 253
tion of the pregnancy without cerclage placement.8 (54%) participated in the study: 127 were randomized
to Shirodkar cerclage and 126 to expectant manage-
The benefit of cervical cerclage for asymptomatic cer- ment. Although cervical shortening was associated
vical shortening diagnosed either by digital examina- with a high risk for preterm birth prior to 33 weeks,
tion or transvaginal ultrasound in women without a placement of a cerclage did not reduce the risk of
prior history suggestive of cervical insufficiency early preterm birth (22% [28/127] in cerclage group
remains controversial.8 Although earlier studies sug- vs. 26% [33/126] in control group; P=0.44).13
gested that cerclage placement in women with an inci-
dental finding of a shortened cervix on ultrasound
examination may improve perinatal outcome, subse-

Table 2

Contraindications to Cervical Cerclage

Maternal Factors Uteroplacental Factors Fetal Factors

Absolute contraindications

Uterine contractions / labor Rupture of fetal membranes Intrauterine fetal demise

Life-threatening maternal Unexplained vaginal bleeding Major fetal anomaly not


conditions that preclude (abruption) compatible with life
anesthesia

Intrauterine infection Gestational age >28 weeks

Relative contraindications

A mucopurulent cervical Placental previa Intrauterine fetal growth


discharge with membrane restriction
opacification

Positive Gram stain or culture on After the limit of fetal


amniotic fluid (because of a failure viability has been reached
rate ≥90%) (≥24 weeks gestation)

Fetal membranes prolapsing


through the cervical os (because of
the high incidence of preterm PROM)

Vaginal infection

CHAPTER 9: OBSTETRIC COMPLICATIONS 219


Contraindications. Contraindications to cerclage are cervical cerclage is best left to the discretion of the
listed in Table 2. Intra-amniotic infection is an abso- obstetric care provider, especially in the setting of a
lute contraindication to cerclage placement,14, 15 and prophylactic cerclage. The selection of the type of cer-
the presence of bacteria on Gram stain or a positive clage placement for emergent cases may be limited by
culture from preoperative amniocentesis is associated the thickness and length of cervical tissue available
with a failure rate of >90%. Preoperative amniocente- for suture placement. The choice of suture material
sis in asymptomatic patients with cervical insuffi- has evolved over the decades from fascia lata or silk to
ciency may be considered prior to emergent cerclage currently a wide selection of non-absorbable sutures,
placement. Although ACOG supports cervical cer- including Mersilene® tape (Dacron® tape), Prolene®
clage placement up to 28 weeks gestation, many prac- (monofilament), and Ethibond® (braided, coated
titioners would not recommend cerclage placement polyester).26 The choice of suture is based on practi-
beyond the limit of fetal viability (≥24 weeks), tioner preference and choice of technique. Shirodkar
because the risk of complications outweighs the cerclage is a single suture placed submucosally
potential benefit.7, 16 Furthermore, placement of a cer- around the cervix at the level of the internal os after
clage in a patient that is in preterm labor (actively con- surgically reflecting the bladder anteriorly and the rec-
tracting) is contraindicated due to the risks of cervical tum posteriorly.27 The suture can be secured anteriorly
trauma and/or uterine rupture caused by maternal con- or posteriorly, and the mucosal incisions closed.
tractions against a surgically sutured cervix. McDonald cerclage is 1 or more purse-string sutures
around the cervix placed without dissection of the
Technical considerations. Once the decision has been bladder or rectum.20 These 2 types of cerclage are
made to proceed with cerclage placement, a preopera- likely equally efficacious, but have never been tested
tive ultrasound examination should be performed to “head-to-head” in a well-designed clinical trial.
confirm fetal viability and exclude major structural Transabdominal cerclage has not been compared
anomalies. Regional anesthesia is preferred to general directly with transvaginal cerclage, and is a far more
endotracheal anesthesia because of the decreased invasive procedure requiring a laparotomy and subse-
maternal morbidity. Prophylactic tocolysis may be quent cesarean delivery. Transabdominal cerclage
used to inhibit transient uterine contractions associ- should therefore be reserved for women in whom a
ated with emergent cerclage placement, but there is no prophylactic cerclage is indicated but technically
objective evidence that tocolysis improves outcome. impossible to place transvaginally or that have failed
Prophylactic broad-spectrum antibiotics are recom- previous prophylactic transvaginal cerclage
mended for emergent cerclage placement. However, placement.28, 29
there are insufficient data to recommend routine use
of prophylactic antibiotics for elective cerclage place- Once a cerclage is in place, weekly or biweekly fol-
ment. If the fetal membranes are found to be prolaps- low-up visits for cervical examinations are probably
ing through the external os, the risk of iatrogenic rup- sufficient in the absence of clinical symptoms. Cervi-
ture of the fetal membranes may be as high as 50%. cal assessment may be by simple bimanual examina-
Trendelenburg position,17 retrograde filling of the tion or by ultrasound to assess the length of cervix,
bladder,18 placement of a 30 mL Foley catheter any loosening of the suture or prolapse of membranes
trancervically past the internal os and filling the bal- through the suture, tearing of the cervix, loss of the
loon,19 placement of a moistened sponge forceps into surgical knot, or loss of the suture. Modified bed rest
the cervical os,20 and/or therapeutic amniocentesis21-23 and “pelvic rest” (no coitus, tampons, or douching)
can be used to reduce the fetal membranes prior to cer- are usually recommended until a favorable gestational
clage placement. In addition, the edges of the cervix age is reached, but without proven benefit. The cer-
can be grasped by sponge forceps to build length to clage is usually removed electively at 37 weeks gesta-
the cervix for cerclage placement.24 tion, but earlier removal may be necessary in the event
of premature uterine contractions. In the setting of
Transvaginal cervical cerclage has been the mainstay preterm PROM, evidence of amnionitis should
for the management of cervical insufficiency. There prompt immediate removal of the cerclage. In preterm
are 2 basic types of transvaginal cerclage placement PROM without evidence of infection, the risk of pre-
techniques: Shirodkar and McDonald.25 The choice of mature delivery with removal must be weighed

220 OBSTETRICS AND GYNECOLOGY—2009


2. Preterm Labor

against the risk of ascending infection with a foreign Preterm (premature) labor refers to labor occurring
body in place.30, 31 prior to 37 completed weeks of gestation. This should
be differentiated from preterm contractions without
Complications. Complications of cervical cerclage documentation of cervical change (effacement and
increase with increasing gestational age and cervical dilatation). Preterm birth occurs in 7%-12% of all
dilatation (Table 3). Cervical cerclage is also associ- deliveries, but accounts for over 85% of all perinatal
ated with increased obstetric interventions, including morbidity and mortality.33, 34
higher rates of admission to hospital, administration
of tocolytics, induction of labor, and cesarean deliv-
ery.5 Puerperal infection occurs in approximately 6%
Etiology

of patients with cerclage, which is twice as common Preterm labor represents a syndrome rather than a
as the incidence in gestational age-matched controls diagnosis since the etiologies are varied. Preterm labor
without cerclage.5, 32 There is no demonstrable associa- may reflect a breakdown in the normal mechanisms
tion between the presence of a cerclage and preterm responsible for maintaining uterine quiescence, or a
PROM remote from placement. short-circuiting or overwhelming of the normal partu-
rition cascade.5, 35 Up to 30% of preterm labor is
thought to result from intra-amniotic infection, and is
likely mediated through the interaction of cytokines
and eicosanoids.36, 37 Definitive diagnosis requires a
positive amniotic fluid culture, but amniotic fluid
markers of infection (such as interleukin-6, glucose,
and white blood cell count) may suggest the diagnosis.
Recently, thrombin has been shown to be a powerful
uterotonic agent providing a mechanism for preterm
labor resulting from placental abruption.

Diagnosis

Preterm labor is a clinical diagnosis characterized by


increasing intensity and frequency of uterine contrac-

Table 3

Complications of Cervical Cerclage

≤48 hours)
Short-term (≤ Long-term (>48 hours)

Premature rupture of fetal membranes Cervical laceration (3%-4%)

Excessive blood loss (may require blood transfusion) Chorioamnionitis (4%)

Pregnancy loss (abortion) Cervical stenosis (1%)

Complications from anesthesia Other rare complications (including


fetal growth restriction, fetal demise,
thrombophlebitis, placental abruption,
bladder pain, migration of suture)

CHAPTER 9: OBSTETRIC COMPLICATIONS 221


tions leading to effacement and dilatation of the tion), but have a higher incidence of adverse effects,
cervix, and culminating in expulsion of the products including maternal tachycardia, EKG changes, and
of conception prior to 37 weeks of gestation. hyperglycemia.55, 58, 59 Indomethacin, although effec-
tive, may be associated with fetal complications such
as oligohydramnios and premature closure of the duc-
tus arteriosus, as well as serious neonatal complica-
Management

Screening tions, such as patent ductus arteriosus that is refrac-


Several risk factors for preterm labor have been tory to pharmacological therapy, especially if given
described (Table 4). However, risk factor screening shortly prior to delivery.60-63 Calcium channel block-
alone will fail to identify over 50% of pregnancies that ers (nifedipine and amlodipine) are becoming
deliver preterm.38, 39 As such, a number of modalities increasing popular agents for tocolysis, since they can
have been developed in an attempt to identify women be orally administered, but maternal hypotension and
at high-risk of preterm birth (Table 5).40-50 Currently, cardiac arrhythmias are a concern.64, 65 Promising
the most reliable screening tests include serial sono- newer agents include oxytocin receptor antagonists
graphic measurement of cervical length42, 43 and/or (used commonly in Europe) and selective cyclooxy-
measurement of fetal fibronectin (fFN) in cervicov- genase-2 inhibitors.66, 67
aginal secretions.46-48
A single course of antenatal glucocorticoids
Clinical Management decreases the incidence of respiratory distress syn-
In the setting of preterm labor, bed rest and hydration drome (RDS), intraventricular hemorrhage (IVH),
are commonly recommended but without proven effi- and necrotizing enterocolitis (NEC) by 50%, and is
cacy.51 Pharmacologic tocolytic therapy remains the recommended for all pregnancies at high risk of
cornerstone of modern management. Although a delivering before 34 weeks gestation with intact
number of alternative agents are now available (Table membranes and before 32 weeks gestation with
6), only ritodrine hydrochloride has received approval preterm PROM.68-70 Maximal benefit is achieved 24-
from the Food and Drug Administration (FDA) of the 48 hours after the initial dose. This effect lasts for 7
United States (FDA) for the treatment of preterm days, but it is unclear what happens thereafter.
labor. The risks and benefits of the individual drugs Repeated courses of steroids are not generally recom-
have been reviewed in detail elsewhere.35, 52-54 All of mended, although a single rescue dose (or rescue
the recommended agents appear equally effective in course) may be appropriate if the initial course was
delaying delivery for 24-48 hours, thereby creating a administered prior to 28-30 weeks gestation.71, 72
window of opportunity for antenatal corticosteroid
administration. There is no good clinical evidence that Tocolysis should be continued until preterm labor has
any of these agents can prolong pregnancy beyond 48 been effectively halted, or empirically until 48 hours
hours and prevent preterm delivery.55 Since no single after the first dose of corticosteroid. Maintenance
agent has a clear therapeutic advantage, the side-effect tocolytic (including terbutaline pump or chronic oral
profile of each of the drugs will often determine which tocolysis) therapy has not been shown to confer any
to use in a given clinical setting. therapeutic benefit73, 74 and poses a risk of adverse side
effects. Similarly, concurrent use of 2 or more
Intravenous magnesium sulfate as a continuous infu- tocolytic agents has not consistently been shown to be
sion has a wide margin of safety and has traditionally more effective than a single agent and exposes the
been regarded as the first-line agent for use in preterm parturient to cumulative risk of side effects, including
labor in North America. More recently, however, this pulmonary edema.75, 76 The use of sequential therapy,
agent has fallen out of favor because of its potential however, may be beneficial if initial therapy is unsuc-
risk of maternal cardiopulmonary failure from over- cessful.77 Although effective in the setting of preterm
dose or neonatal rickets and neurologic injury from PROM, there is no role for broad-spectrum antibiotic
prolonged or excessive use.56, 57 Adrenergic agonists therapy to prolong latency in preterm labor with intact
are commonly used (eg, subcutaneous terbutaline in membranes.78
an injection, continuous infusion or oral administra-

222 OBSTETRICS AND GYNECOLOGY—2009


Table 4

Risk Factors for Preterm Birth

Nonmodifiable Possibly Modifiable

Prior preterm birth Cigarette smoking

African American Illicit substance use (cocaine)

Age <18 or >40 years Absent prenatal care

Low socioeconomic status Poor nutrition

Cervical injury or anomaly Anemia

Uterine anomaly or fibroids Low prepregnancy weight

Excessive uterine activity Bacteriuria / urinary tract infection

Premature cervical dilation (>2 cm) Genital infection and/or gingival infection
or effacement (>80%)

Overdistended uterus (twins, polyhydramnios) Strenuous work

Vaginal bleeding High personal stress

CHAPTER 9: OBSTETRIC COMPLICATIONS 223


Table 5

Screening for Preterm Birth

Screening Modality Comment

Home uterine activity Although an increase in uterine activity is a prerequisite for


monitoring (HUAM) preterm labor, HUAM of women at low risk and high risk has not
been shown to reduce the incidence of preterm delivery.

Cervical evaluation
Serial digital examination Serial digital evaluation of the cervix has not been shown to be
useful in predicting preterm delivery. An abnormal cervical find-
ing (shortening and/or dilatation) is associated with preterm
delivery in only 4% of low-risk women and 12%-20% of high-risk
women.

Serial sonographic evaluation Real-time sonographic evaluation of the cervix has demon-
strated an inverse correlation between cervical length and risk
of preterm delivery. If the cervical length is below the 10th per-
centile for gestational age, there is a 6-fold increased risk of
delivery prior to 35 weeks gestation.

Vaginal infection Vaginal infections (specifically bacterial vaginosis, Neisseria


gonorrhoea, Chlamydia trachomatis, Group B Streptococcus,
Ureaplasma urealyticum and Trichomonas vaginalis) have
been associated with preterm labor. However, screening and
treating for such organisms has not been demonstrated to
impact preterm birth.

Biochemical markers
Fetal fibronectin (fFN) Elevated levels of fFN in cervicovaginal secretions are associ-
ated with premature delivery and may reflect separation of the
fetal membranes from the maternal decidua. The real value of
this test appears to lie in its negative predictive value (99% of
patients with a negative fFN test will not deliver within 7 days),
which may prevent unnecessary hospitalization. In a low-risk
population, the predictive value of a positive fFN test at 22-24
weeks gestation for spontaneous preterm delivery prior to 28
weeks and 37 weeks is only 13% and 36%, respectively.

Endocrine markers
Salivary estriol Progesterone withdrawal is not a prerequisite for labor in
the human and serum progesterone levels, andprogesterone/
17 ␤-estradiol ratios are not predictive of preterm labor. How-
ever, maternal salivary estriol can accurately identify activation
of the fetal hypothalamic-pituitary-adrenal axis that occurs prior
to the onset of labor, both at term and preterm. The detection of
elevated levels of estriol in maternal saliva (≥2.1 ng/mL) is pre-
dictive of delivery prior to 37 weeks gestation in a high-risk pop-
ulation with a sensitivity of 68%-87% and specificity of 77% (and
a false positive rate of 23%).

224 OBSTETRICS AND GYNECOLOGY—2009


Table 6

Tocolytic Agents Commonly Used for the Management of Preterm Labor

Agent Administration Efficacy Major Maternal Major Fetal


(Dosage) Side Effects Side Effects

Magnesium sulfate IV (4-6 g bolus, then Effective Nausea, ileus, headache, weakness Decreased beat-to-beat variability
2-3 g/h infusion) Hypotension Neonatal drowsiness, hypotonia
Oral maintenance Not effective Pulmonary edema Ileus
(100-120 mcg Q4h) Cardiorespiratory arrest Congenital ricketic syndrome (with treatment >3 weeks)

␤-adrenergic agonists IV (2 mcg/min infusion, Effective Jitteriness, anxiety, restlessness, Fetal tachycardia
Terbutaline sulfate maximum 80 mcg/min) nausea, vomiting, rash Hypotension
SC (0.25 mcg Q20 min) Effective Cardiac dysrhythmias, myocardial Ileus
hypotension, tachycardia Hyperinsulinemia, hypoglycemia, hyperbilirubinemia
Oral maintenance (2.5-5 mcg Q4-6h) Effective Pulmonary edema Hypocalcemia
IV pump (0.05 mL/h) Not effective Paralytic ileus

Prostaglandin inhibitors
Indomethacin Oral (25-50 mcg Q4-6h) Effective Gastrointestinal effects (nausea, Transient oliguria, oligo-hydramnios
heartburn), headache, rash Premature closure of neonatal ductus
Rectal (100 mcg BID) Effective Interstitial nephritis arteriosus and persistent pulmonary hypertension
Increased bleeding time (most Necrotizing enterocolitis,
common with aspirin) intraventricular hemorrhage

Calcium channel blockers


Nifedipine Oral (20-30 mcg Q4-8h) Effective Hypotension, reflex tachycardia,
headache, nausea, flushing

Oxytocin antagonists
Atosiban IV (1 mM/min infusion) Effective Nausea, vomiting, headache, Inhibit lactation
chest pain, arthralgias

CHAPTER 9: OBSTETRIC COMPLICATIONS


The only tocolytic agent approved by the Food and Drug Administration of the U.S.
Efficacy is defined as proven benefit in delaying delivery by 24-48 hours as compared with placebo or standard control.

225
IM, intramuscular; IV, intravenous; SC, subcutaneous; TD, transdermal.
Modified from Norwitz ER, Robinson JN, Challis JRG. The control of labor. N Engl J Med. 1999;341:660-666.
3. Post-term Pregnancy

Post-term (prolonged) pregnancy refers to a preg- fetal weight > 4500 g84 ) (2.5%-10% vs. 0.8%-
nancy that has extended to or beyond a gestational age 1%).85, 86 Complications associated with fetal macro-
of 42.0 weeks (294 days) from the first day of the last somia include prolonged labor, cephalopelvic dis-
menstrual period.79, 80 In the United States, around proportion and shoulder dystocia, with resultant
10% of all singleton pregnancies continue beyond 42 risks of orthopedic or neurologic injury.84 Post-term
weeks of gestation and 4% continue beyond 43 pregnancies are also at increased risk of umbilical
completed weeks in the absence of obstetric interven- cord compression from oligohydramnios, nonreas-
tion.79, 80 Post-term pregnancy should be differentiated suring fetal antepartum or intrapartum assessment,
from a post-mature pregnancy, which is a distinct clin- meconium aspiration, short-term neonatal complica-
ical fetal syndrome consisting of a fetus that has wrin- tions (hypoglycemia, seizures) and long-term neuro-
kled, peeling skin with a thin body, and meconium- logic sequelae.
stained skin and nails that is diagnosed postnatally.81, 82
Maternal risks of prolonged pregnancy include an
increase in labor dystocia (9%-12% vs. 2%-7% at
term), an increase in severe perineal injury (3.3% vs.
Etiology

Primiparity and prior post-term pregnancy are the 2.6% at term) and a doubling in the rate of cesarean
most common identifiable risk factors for a post-term delivery.87-89 The latter is associated with higher risks
pregnancy. Rarely, post-term pregnancy may be asso- of complications such as endometritis, hemorrhage,
ciated with placental sulfatase deficiency or fetal and thromboembolic disease.
anencephaly (in the absence of polyhydramnios).
Genetic predisposition may also play a role. However,
in the vast majority of cases, the cause of post-term
Management

pregnancy is unknown.79 An accurately estimated date of delivery should be


calculated early in pregnancy. This may be based
upon a known last menstrual period in women with
regular, normal menstrual cycles and confirmatory
Diagnosis

Accurate pregnancy dating is critical to the diagnosis. uterine sizing. Uncertainty in historical or physical
The incidence of post-term pregnancy depends upon dating parameters should prompt ultrasound assess-
the patient population, including such factors as the ment of gestational age.90
percentage of primigravid women, women with preg-
nancy complications, the prevalence of ultrasound Post-term pregnancy is an accepted indication for
assessment of gestational age and the frequency of antenatal fetal monitoring. ACOG has recommended
spontaneous preterm birth. Local practice patterns, that antepartum fetal surveillance be initiated after 42
such as the rates of scheduled cesarean delivery and weeks of gestation, without a specific recommenda-
routine labor induction, will also affect the overall tion regarding type of test or frequency.79, 80 Options for
incidence of post-term birth. evaluating fetal well-being include weekly or twice
weekly nonstress testing with amniotic fluid volume
assessment, the biophysical profile (BPP) or modified
BPP, the oxytocin challenge test or a combination of
Complications

Post-term pregnancy is associated with both fetal these modalities; no single method has been shown to
and maternal risks. Perinatal mortality (stillbirths be superior. Umbilical artery Doppler velocimetry
plus early neonatal deaths) at ≥42 weeks of gestation testing alone has not been shown to be beneficial in
is twice that at term (4-7 vs. 2-3 per 1000 deliveries) monitoring the post-term fetus.79 It should be noted
and increases 4-fold at 43 weeks and 5- to 7-fold at that there is insufficient evidence to show that initiat-
44 weeks.79, 80, 83 Chronic uteroplacental insuffi- ing antenatal surveillance between 40 and 42 weeks of
ciency, asphyxia and intrauterine infection all con- gestation improves pregnancy outcome or confers any
tribute to the excess perinatal deaths. Post-term benefit to the fetus.79
infants are larger than term infants, with a higher
incidence of macrosomia (defined as an estimated

226 OBSTETRICS AND GYNECOLOGY—2009


4. Hypertensive Disorders
of Pregnancy

Delivery is recommended when the risks to the fetus Hypertensive disorders of pregnancy are the second
by continuing the pregnancy are greater than those most common cause of maternal death in the United
faced by the neonate after birth. Both expectant man- States (behind venous thromboembolic disease),
agement and labor induction are associated with low accounting for 15%-20% of all maternal deaths.94, 95
complication rates in low-risk post-term gravida.91-93 Hypertension is also associated with high perinatal
Factors that need to be considered include gestational mortality and morbidity rates, primarily due to iatro-
age, results of antepartum fetal assessment, favorabil- genic prematurity.96 Hypertensive disorders of preg-
ity of the cervix, and maternal preference. Delivery nancy can be classified into 4 categories:
should be initiated immediately if there is evidence of
fetal compromise or oligohydramnios. There does 1.) Chronic hypertension is defined as hypertension
appear to be a small advantage to routine induction of prior to pregnancy and should also be considered in
labor at 41 weeks gestation, regardless of parity or parturients with a sustained BP ≥140/90 prior to 20
method of induction.87, 88 In women with unfavorable weeks gestation. Such pregnancies are at increased
cervical exams, the routine use of preinduction cervi- risk of superimposed preeclampsia, uteroplacental
cal ripening has resulted in fewer failed and serial insufficiency and IUGR, placental abruption and still-
inductions, lower fetal and maternal morbidity, a birth. Angiotensin converting enzyme (ACE)
shorter hospital stay, lower medical cost and possibly inhibitors should be discontinued in pregnancy. These
a lower rate of cesarean delivery in the general obstet- drugs have not consistently been associated with an
ric population. The post-term fetus is at increased risk increased risk of structural anomalies in the first
of intrapartum fetal heart rate abnormalities and pas- trimester over baseline, but exposure in the latter half
sage of meconium. For this reason, continuous elec- of pregnancy has been associated with progressive
tronic fetal monitoring in labor is recommended for and irreversible renal injury in the fetus, including
such pregnancies. renal dysplasia and hypocalcified calvaria resulting
from the blockade of the conversion of angiotensin 1
to angiogensin 2 in the developing kidneys and low
fetal blood pressure on the fetal skull, respectively.97, 98
Because the perinatal mortality associated with mater-
nal chronic hypertension is increased above baseline
(6-25/1000 vs. 6.4/1000 in normotensive pregnan-
cies),99 antepartum fetal testing (weekly non-stress
tests, serial ultrasound examinations for fetal growth)
should be initiated after 32 weeks gestation. Delivery
should ideally be achieved by 40 weeks with a favor-
able cervix.

2.) Chronic hypertension with superimposed


preeclampsia is defined as pre-existing chronic hyper-
tension with worsening features during pregnancy,
and may be difficult to differentiate from preeclamp-
sia.

3.) Pregnancy-induced hypertension (PIH), also


known as transient hypertension or gestational non-
proteinuric hypertension, refers to persistent elevation
of BP ≥140/90 in the third trimester without evidence
of preeclampsia in a previously normotensive woman.
It is a diagnosis of exclusion. PIH likely represents an
exaggerated physiologic response of maternal cardio-
vascular system to pregnancy. It is rarely associated
with adverse maternal or fetal outcome, but may be

CHAPTER 9: OBSTETRIC COMPLICATIONS 227


difficult to distinguish from preeclampsia. PIH (but not
preeclampsia) is associated with an increased risk of
Diagnosis

chronic hypertension in later life. Preeclampsia is a clinical diagnosis encompassing 3


elements: (1.) new-onset hypertension (defined as a
4.) Preeclampsia, also known as gestational protein- sustained sitting BP ≥140/90 in a previously nor-
uric hypertension, complicates 6%-8% of all pregnan- motensive woman); (2.) new-onset proteinuria (>300
cies.94, 100, 101 It is an idiopathic multisystem disorder mg/24 h or ≥1+ on a clean-catch urinalysis in the
specific to human pregnancy and the puerperium. absence of urinary infection); and (3.) nondependent
More precisely, it is a disease of the placenta since it edema.100, 101 However, more recent consensus reports
occurs also in pregnancies where there is trophoblast have suggested eliminating edema as a criterion for
but no fetal tissue (complete molar pregnancies). the diagnosis.109 A definitive diagnosis of preeclamp-
Preeclampsia is discussed in more detail below. sia should only be made after 20 weeks gestation. Evi-
dence of gestational proteinuric hypertension prior to
20 weeks should raise the possibility of an underlying
molar pregnancy, collagen vascular disease, antiphos-
Etiology

The pathogenesis of preeclampsia remains poorly pholipid antibody syndrome, drug withdrawal, multi-
understood. At present, 5 hypotheses are the subject of ple pregnancy, or chromosomal abnormality (trisomy)
intense investigation:100-103 (1.) genetic imprinting; (2.) in the fetus.
immune maladaption; (3.) placental ischemia; (4.)
generalized endothelial dysfunction; and (5.) defec- Preeclampsia is classified as either “mild” or “severe”
tive-free fatty acid, lipoprotein and/or lipid peroxidase (there is no category of “moderate” preeclampsia). A
metabolism. However, there is as yet no single unify- diagnosis of severe preeclampsia should be enter-
ing theory that can account for all of the findings in tained in women with new-onset proteinuric hyperten-
preeclampsia. Although the pathophysiology of sion along with 1 or more of a series of complications
preeclampsia is not well understood, it is clear that the (Table 7). IUGR was excluded from the criteria in
blueprint for its development is laid down early in 2000 by the National High Blood Pressure in Preg-
pregnancy. It has been suggested that the pathologic nancy Working Group because of inconsistencies in
hallmark is a complete or partial failure of the second its definition, but was still included as a criterion for
wave of trophoblast invasion from 16-20 weeks of the diagnosis of severe preeclampsia by ACOG in
gestation that, in normal pregnancies, causes destruc- 2002.101 Mild preeclampsia includes all women with
tion of the muscularis layer of the spiral arterioles.104-106 preeclampsia, but without any features of severe dis-
As pregnancy progresses, the metabolic demands of ease.
the fetoplacental unit increase. Because of the abnor-
mally shallow invasion of the placenta in preeclampsia
and the lack of vascular remodeling, the spiral arteri-
Management

oles are unable to dilate to accommodate the required Timing of Delivery


increase in blood flow, resulting in “placental dysfunc- Delivery is the only effective treatment for preeclamp-
tion” that manifests clinically as preeclampsia. Recent sia. Delivery is recommended in women with mild
data suggest that excessive placental production of the preeclampsia once a favorable gestational age has been
fms-like tyrosine kinase receptor (also known as solu- reached (>36-37 weeks) and in all women with severe
ble Flt-1 [sFlt-1]), the soluble form of the vascular preeclampsia regardless of gestational age (with the
endothelial growth factor (VEGF) receptor type I that exception of severe preeclampsia due to proteinuria
binds both circulating VEGF and placental growth fac- alone or IUGR remote from term with good fetal test-
tor, may be responsible for the widespread endothelial ing). There has also been a recent trend towards expec-
injury that characterizes preeclampsia.107, 108 In this way, tant management of severe preeclampsia by BP criteria
sFlt-1 may be the elusive “toxemia factor” of alone <32 weeks gestation.110, 111 Every effort should be
preeclampsia. Although attractive, this hypothesis made to delay delivery for 24-48 hours to administer
remains to be validated. antenatal corticosteroids, if indicated.

228 OBSTETRICS AND GYNECOLOGY—2009


Table 7

Diagnostic Features of Severe Preeclampsia

Symptoms

Symptoms of central nervous system dysfunction (blurred vision, scotomata, altered mental status, and/or
severe headache)

Symptoms of liver capsule distention or rupture (right upper quadrant and/or epigastric pain)

Signs

Severe elevations in BP (defined as BP ≥160/110 on 2 separate occasions at least 6 hours apart)

Pulmonary edema

Eclampsia (generalized seizures and/or unexplained coma in the setting of preeclampsia and in the absence of
other neurologic conditions)

Cerebrovascular accident

Cortical blindness

Fetal intrauterine growth restriction

Laboratory Findings

Proteinuria (>5 g/24 hours)

Renal failure or oliguria (<500 mL/24 hours)

Hepatocellular injury (serum transaminase levels ≥2 x normal)

Thrombocytopenia (<100,000 platelets/mm3)

Coagulopathy

HELLP (Hemolysis, elevated liver enzymes, low platelets) syndrome

Route of Delivery delivery, and fetal status and presentation. In general,


Severe preeclampsia does not mandate immediate less than one-quarter of women with severe
cesarean delivery. The decision of whether to proceed preeclampsia remote from term with an unfavorable
with cesarean or induction of labor and attempted cervix will have a successful vaginal delivery.112, 113
vaginal delivery should be individualized based on Cervical ripening agents may be used if the cervix is
such factors as parity, gestational age, cervical exami- not favorable prior to induction, but prolonged induc-
nation (Bishop score), maternal desire for vaginal tions should be avoided.

CHAPTER 9: OBSTETRIC COMPLICATIONS 229


Treatment of Hypertension logic sequelae or renal failure are rare. Diuresis (>4
The use of antihypertensive agents to control mildly liters/day) often heralds clinical resolution. BP that
elevated BP in the setting of preeclampsia has not remains elevated more than 12 weeks postpartum are
been shown to alter the course of the disease, nor to unlikely to be related to preeclampsia. Patients with
diminish perinatal morbidity or mortality, and may severe hypertension (160/100 mmHg) can be treated
even reduce birth weight. However, antihypertensive with oral antihypertensive medications until their 6-
agents should be administered to prevent a maternal week postpartum check, and then weaned off. If they
cerebrovascular accident (stroke) with severe hyper- continue to require antihypertensive medication, they
tension while effecting delivery. Most clinicians should be referred to an internist for further
would recommend initiation of antihypertensive ther- investigation.121, 122
apy for a systolic BP ≥160 mm Hg and/or diastolic BP
≥110 mm Hg, although these cut-offs have not been Recurrence Risk and Prevention
tested prospectively.114, 115 Treatment options are sum- The risk of recurrence of preeclampsia in a subse-
marized in Table 8. Sodium restriction and diuretics quent pregnancy is related to the severity and nature
have no role in therapy. Restricted physical activity of the presentation and to the gestational age at pre-
(bed rest) can lower BP, although its efficacy for sentation.123 Preeclampsia is a disorder of placental
improving perinatal outcome has not been proven. implantation and therefore not entirely preventable.
Despite promising early studies, low-dose aspirin
Intrapartum Anesthesia (acetylsalicylic acid [ASA]) and/or supplemental cal-
Neuraxial techniques (epidural, spinal) can be safely cium does not appear to prevent preeclampsia recur-
administered in the setting of preeclampsia (in the rence in either high- or low-risk parturients.124, 125 A
absence of thrombocytopenia) with close attention to recent meta-analysis suggests that low-dose aspirin
volume expansion and anesthetic technique. (80 mg per day) may be useful in preventing
Hypotension is a major concern, because preeclamp- preeclampsia, but only in women with prior early,
sia causes total body fluid overload but depleted severe preeclampsia.126 Moreover, low-dose aspirin in
intravascular volume. Airway edema and exacerba- low-risk women may increase their risk of placental
tion of hypertension with intubation can complicate abruption. Women at high-risk for preeclampsia
induction of general anesthesia. should be seen early in pregnancy to establish accu-
rate pregnancy dating, and to perform baseline BP and
Seizure Prophylaxis laboratory tests. Measurement of BP and urine protein
Seizure prophylaxis is generally initiated during labor at regular intervals in the late second and third
or while administering corticosteroids or trimesters is critical for timely diagnosis of
prostaglandins prior to planned delivery and contin- preeclampsia.
ued until 24-48 hours postpartum, when the risk of
seizures is decreased.116 Magnesium sulfate is the drug
of choice to prevent seizures (eclampsia) in the setting
of mild or severe preeclampsia (Table 9).117, 118 The
incidence of seizures is much lower in women with
nonproteinuric mild hypertension (0.1% as compared
with 1%-2% for severe preeclampsia119), and it is safe
to withhold seizure prophylaxis in this setting. Mag-
nesium sulfate must be given intravenously or by
intramuscular injection, as it is not absorbed orally.
Because magnesium is renally excreted, infusion rates
should be decreased for maternal serum creatinine
levels of 1.0 mg/dL or higher.120

Postpartum Care
Preeclampsia and its complications resolve following
delivery, often within a few days. Permanent neuro-

230 OBSTETRICS AND GYNECOLOGY—2009


Table 8

Pharmacologic Management of Acute Hypertensive Crisisa

Drug Dosing Comment

Recommended first-line therapy

Hydralazine 5 mg IV push Q 10 min x 2 doses; then 10 mg Be aware of hypotension and


IV push Q 20 min as needed until blood potential to adversely affect
pressure has stabilized at 140-150/90-100 uteroplacental perfusion

Labetalol 10-20 mg IV push; repeat Q 10-20 min with Be aware of hypotension and poten-
doubling doses (not to exceed 80 mg in any tial to adversely affect uteroplacental
single dose) to a maximum of 300 mg total perfusion

Nifedipine 10 mg orally Q 30 min x 2 doses; then Sublingual nifedipine is best


10-20 mg orally Q 4-6 hourly avoidedb

Recommended therapy in women refractory to first-line agents

Sodium nitroprusside 0.5–3.0 mcg/kg/min IV infusion (not to Should be used only by someone
exceed 800 mcg/min) with critical care experience

Nitroglycerin 5 mg/min IV infusion, increase as required Relatively contraindicated in the


every 5 min to maximum dose of 100 mg/min setting of hypertensive encephalopathy
as it may increase cerebral blood flow
and intracranial pressure

a Adapted from Repke JT. Preeclampsia and hypertension. In: Repke JT, ed. Intrapartum Obstetrics. New York, NY: Churchill
Livingstone; 1996:271.
b Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules
given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-1331.

Table 9

Prevention of Seizures in Parturients with Preeclampsia

Drug Loading Dose Maintenance Dose Therapeutic Level

Recommended first-line therapy

Magnesium sulfate 4-6 g IV over 10-20 min 2-3 g/h IV infusionb 4-8 mEq/La
10 g IM (5 g IM into each buttock) 5 g IM every 4 h as above

Recommended therapy in women refractory to magnesium sulfate

Phenytoin 1-1.5 g over 1 h (depending 250-500 mg Q 10-12 h 10-20 mcg/mL


on body weight) orally or IV

a Adapted from Repke JT. Preeclampsia and hypertension. In: Repke JT, ed. Intrapartum Obstetrics. New York, NY:
Churchill Livingstone;1996: 271.
b Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules
given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-1331.

CHAPTER 9: OBSTETRIC COMPLICATIONS 231


5. Intrauterine Fetal Demise

Intrauterine fetal demise (IUFD)—also known as IUFD by documenting the absence of fetal cardiac
stillbirth—is defined in the United States as fetal activity. Other sonographic findings in later preg-
demise after 20 weeks gestation and prior to deliv- nancy may include scalp edema, overlapping
ery.127 In the United States, the stillbirth rate decreased sutures and fetal maceration.
from 15.8 per 1000 total births in 1960 to 7.5 per 1000
births in 1990.99, 128 Risk factors for IUFD include
extremes of maternal age, multiple pregnancy, post-
Management

term pregnancy, male fetus, fetal macrosomia and Every effort should be made to avoid cesarean deliv-
maternal disease, such as pregestational diabetes, sys- ery in the setting of IUFD. As such, expectant man-
temic lupus erythematosus (SLE) and preeclamp- agement is often recommended. Latency (the period
sia.129, 130 from fetal demise to delivery) varies depending on the
underlying cause and gestational age. In general, the
earlier the gestational age, the longer the latency
period. Overall, >90% of women will go into sponta-
Etiology

Causes of IUFD can be identified in only around 50% neous labor within 2 weeks of fetal death. However,
of cases (Table 10). Pathologic examination of the many women find the prospect of carrying a dead
fetus and placenta/fetal membranes is the single most fetus distressing and want the pregnancy terminated as
useful test to identify a cause for the IUFD. Early soon as possible. Management options include surgi-
detection and appropriate management of underlying cal dilatation and evacuation or induction of labor
maternal disorders (diabetes, preeclampsia) may with cervical ripening, if indicated. Around 20%-25%
reduce the risk of IUFD.131, 132 Fetal karyotyping should of women who retain a dead singleton fetus for longer
be considered in all cases of fetal death to identify than 3 weeks will develop disseminated intravascular
chromosomal abnormalities, particularly in cases with coagulopathy (DIC) due to excessive consumption of
documented fetal structural abnormalities. Approxi- clotting factors.137, 138 Therefore, delivery should be
mately 6%-10% of stillborn fetuses have abnormal effected within this time period.
karyotypes.133 Amniocentesis may be recommended
to salvage viable amniocytes for cytogenetic analysis Death of a Co-twin
prior to delivery. Fetal-maternal hemorrhage (fetal The death of 1 twin confers an increased risk of major
cells spilling into maternal circulation) occurs in all morbidity to the surviving twin, including IUFD, neu-
pregnancies, but is usually minimal (<0.1 mL total rologic injury, multiorgan system failure, thrombosis,
volume). In rare instances, fetal-maternal hemorrhage distal limb necrosis, placental abruption and prema-
may be massive, leading to fetal demise. The Klei- ture labor.99-101 The prognosis for the surviving twin is
hauer-Betke (acid elution) test allows an estimate of dependent on the cause of death, gestational age,
the volume of fetal blood in the maternal circulation, chorionicity and time interval between death of the
and should be drawn within 6 - 8 hours of the pur- first twin and delivery of the second. Dizygous twin
ported time of bleeding episode due to rapid clearance pregnancies do not share circulation, and the death of
of fetal cells from maternal circulation.134 Intra-amni- 1 twin may have little impact on the surviving twin.
otic infection resulting in fetal death is usually evident The dead twin may be resorbed completely or become
on clinical exam. Placental membrane culture and compressed and incorporated into the membranes
autopsy examination of the fetus, placenta/fetal mem- (fetus papyraceus). DIC in the surviving fetus and/or
branes and umbilical cord may be useful. Fetal x-rays mother is rare.102 On the other hand, some degree of
or MRI may sometimes be valuable if autopsy is shared circulation can be demonstrated in almost all
declined.135, 136 monozygous twin pregnancies, and death of 1 fetus in
this setting carries an increased risk of death of its co-
twin due to profound hypotension and/or purported
transfer of thromboplastic proteins from the dead fetus
Diagnosis

The inability to identify fetal heart tones or the to the live fetus.143 If it survives, the co-twin, has a 40%
absence of uterine growth may suggest the diagno- risk of developing neurologic injury (multicystic
sis. Ultrasound is the gold standard to confirm an

232 OBSTETRICS AND GYNECOLOGY—2009


6. Intrauterine Growth Restriction

encephalomalacia), which may not be prevented by Birth weight is a function of both gestational age and
immediate delivery.144, 145 Therefore, management of a rate of fetal growth. Intrauterine growth restriction
surviving co-twin depends on chorionicity and gesta- (IUGR) refers to any fetus that fails to reach its full
tional age. Fetal surveillance (kickcharts, nonstress growth potential. In the United States, 4%-8% of
testing, biophysical profile) should be instituted on a fetuses are diagnosed with IUGR.146, 147 IUGR should
regular basis, and delivery considered in the setting of be differentiated from the term SGA (small for gesta-
nonreassuring fetal testing or at a favorable gesta- tional age), a term commonly used by the pediatri-
tional age. cians to represent both constitutionally small
neonates that are healthy and the growth restricted
fetus that is at risk for poor perinatal outcomes.148

Etiology

IUGR likely represents the clinical end-point of many


different fetal, uteroplacental, and maternal condi-
tions (Table 11). Every attempt should be made to
determine the cause prior to delivery.

Diagnosis

The clinical diagnosis of IUGR is difficult, and physi-


cal examination alone will fail to identify over 50% of
IUGR fetuses. If the fundal height measurement is
significantly less than expected (<3-4 cm for gesta-
tional age), an ultrasound examination should be per-
formed. IUGR is a radiologic diagnosis that requires
either: (1.) an estimated fetal weight (EFW) <3rd per-

Table 10

Causes of Intrauterine Fetal Demise (IUFD)

Maternal causes Uteroplacental causes Fetal causes

Underlying medical conditions Placental abruption Fetal chromosomal /


(diabetes mellitus, thyroid disease, genetic anomalies
antiphospholipid antibody syndrome)

Preeclampsia Placenta previa Fetal structural abnormalities

Isoimmunization Vasa previa Intra-amniotic infection

Illicit drug use (cocaine) Fetal-maternal hemorrhage Complications of multiple


pregnancies (including twin-to-twin
transfusion syndrome)

Antepartum drug / toxin exposure Cord accident

CHAPTER 9: OBSTETRIC COMPLICATIONS 233


centile (2 standard deviations from the mean) for ges- pregnancies should be followed on a regular basis to
tational age, or (2.) an EFW <10th percentile for gesta- exclude this complication.
tional age along with evidence of fetal compromise
(usually oligohydramnios or abnormal umbilical IUGR fetuses can undergo vaginal delivery and
artery Doppler velocimetry).146,147,149 Fetuses who are cesarean delivery should be reserved for the usual
<10th percentile without evidence of compromise obstetric indications. However, up to 50%-80% of
should be referred to as SGA and not IUGR. Accurate IUGR fetuses will show evidence of nonreassuring
gestational age dating is clearly a prerequisite for the fetal testing in labor requiring cesarean delivery.146
diagnosis. A small calcified (Grade 3) placenta Timing of delivery also depends on the precise gesta-
detected on ultrasound examination in association tional age, any superimposed maternal conditions (eg,
with a small biparietal circumference may also be sug- severe preeclampsia), the presence or absence of
gestive of an IUGR pregnancy.150 abnormal umbilical cord Dopplers (reversed end-
diastolic flow), whether or not there has been any
interval fetal growth over a 2- to 3-week period, and
whether or not the IUGR fetus is a singleton vs. a mul-
Complications

IUGR infants have higher rates of perinatal morbidity tiple gestation in which the other fetus(es) are growing
and mortality as compared with appropriate for gesta- appropriately.154 If a premature delivery <34 weeks is
tional age (AGA) fetuses for any given gestational anticipated, a course of antenatal corticosteroids may
age. Neonatal morbidity (meconium aspiration syn- be warranted. Note that antepartum fetal testing
drome, hypoglycemia, polycythemia, pulmonary (including the BPP and umbilical artery Doppler
hemorrhage) may be present in up to 50% of IUGR velocimetry) may temporarily worsen in the 24-48
neonates.146,147,149,151 Premature IUGR infants also have hours following steroid administration in some
difficulty with nutritional support, and many develop fetuses.155
feeding intolerance and failure to thrive in the
NICU.152 Long-term studies show a 2-fold increased
incidence of cerebral dysfunction (ranging from
minor learning disability to cerebral palsy) in IUGR
infants delivered at term, and an even higher incidence
if the infant was born preterm. Epidemiological stud-
ies also suggest that these infants may also be at higher
risk for developing chronic disease in adulthood such
as diabetes, hypertension, stroke and coronary heart
disease (the Barker Hypothesis).153

Management

Bed rest and low-dose aspirin have not been shown to


prevent IUGR in women at high risk; however, a
recent meta-analysis suggests that women with prior
history of an IUGR pregnancy with early severe
preeclampsia may benefit from empiric low-dose
aspirin therapy during subsequent pregnancies.126
Principles of management of IUGR pregnancies
include identification of women at high risk, early
antepartum diagnosis, attempts to identify etiology
(karyotype, infection, antiphospholipid antibody syn-
drome), regular (usually twice-weekly) fetal surveil-
lance and appropriate timing of delivery. IUGR may
be the first manifestation of preeclampsia, and such

234 OBSTETRICS AND GYNECOLOGY—2009


Table 11

Risk Factors for Intrauterine Growth Restriction (IUGR)

Maternal Causes

Demographic Drug / toxin Underlying medical


factors exposure conditions Infections

Prior IUGR infant Illicit drugs (cocaine) Hyperthyroidism Malaria


African American Cigarette smoking Hemoglobinopathies Rubella
Chemotherapy Chronic pulmonary disease Cytomegalovirus
Cyanotic heart disease HIV
Diabetes mellitus with Varicella
vascular disease
Anemia
Malnutrition

Uteroplacental Causes

Uteroplacental insufficiency Velamentous cord insertion

Chronic hypertension

Preeclampsia

Antiphospholipid antibody syndrome

Unexplained chronic proteinuria

Chronic placental abruption

Fetal Causes

Genetic factors Fetal structural anomalies Multiple pregnancy

Fetal chromosomal anomalies Cardiovascular anomalies Polyhydramnios /


(including trisomy 18>13>21 and Bilateral renal agenesis oligohydramnios
sex chomosome abnormalities) Single umbilical artery sequence (including
twin-to-twin transfusion
Single gene defects (such as syndrome)
phenylketonuria and dwarfism)

Confined placental mosaicism

CHAPTER 9: OBSTETRIC COMPLICATIONS 235


7. Multiple Pregnancy

Multiple pregnancies complicate 1%-2% of all deliv- monochorionic (no peak, but a thin filmy mem-
eries and are becoming increasingly common, primar- brane).162 Identification of separate sex fetuses or 2
ily as a result of assisted reproductive technology separate placentae confirms dichorionic/diamniotic
(ART). This is especially true of higher-order multiple placentation.
pregnancies (triplets and up) which now constitute
0.103% of all births.156 The vast majority (97%-98%)
of multiple gestations are twin pregnancies.
Complications

Overall, antepartum complications develop in 80% of


multiple pregnancies, compared with around 30% of
singleton gestations (Table 12).163 Preterm delivery is
Diagnosis

Multiple pregnancy should be suspected in women at the most common complication, and the risk of
high risk, women with excessive symptoms of preg- preterm delivery increases as fetal number increases:
nancy (such as nausea and vomiting), or uterine size the average length of gestation is 40 weeks in single-
larger than expected. The overall incidence of dizy- tons, 37 weeks in twins, 33 weeks in triplets, and 29
gous twinning in the U.S. is around 1 in 89 pregnan- weeks in quadruplets.164 Fetal growth discordance
cies, and is influenced by a number of epidemiologic (defined as a ≥25% difference in EFW between
factors, including a family or personal history of mul- fetuses of the same pregnancy) occurs in 5%-15% of
tiple pregnancy, advanced maternal age, multiparity, twins and 30% of triplets, and is associated with a 6-
African American, and ART.157 Monozygous twin- fold increase in perinatal mortality.165,166 Cord entan-
ning, on the other hand, is a random event that occurs glement is rare (1 in 25,000 births), but may occur in
in around 1 in 300 pregnancies (although the risk may up to 70% of monochorionic/monoamniotic pregnan-
be increased 2- to 3-fold with in vitro fertilization).158 cies, and accounts for >50% of perinatal mortality in
Ultrasound will confirm the diagnosis. this subgroup.163,167,168 Maternal complications include
an increased risk of gestational diabetes, preeclamp-
Zygosity and Chorionicity sia, anemia, cholestasis of pregnancy,169 cesarean
80% of twin pregnancies are dizygous (derived from 2 delivery (due primarily to malpresentation), and post-
separate embryos). Perinatal mortality is higher with partum hemorrhage.
monozygous (30%-50%) than with dizygous twins
(10%-20%). Chorionicity refers to the arrangement of Twin polyhydramnios/oligohydramnios
membranes in multiple pregnancies. In monozygous (“poly/oligo”) sequence results from an imbalance in
twinning, the timing of the cell division determines blood flow from the “donor” twin to the “recipient.”
the chorionicity. If the zygote divides within 3 days of Both twins are at risk for adverse events. Twin-to-twin
fertilization, the result is dichorionic/diamniotic pla- transfusion syndrome is a subset of polyhydram-
centation (30% of all monozygous pregnancies); if the nios/oligohydramnios sequence seen in 15% of
division occurs between day 3 and day 8, the result is a monochorionic pregnancies,170, 171 and is due to unbal-
monochorionic/diamniotic pregnancy (65%); anced vascular communications between the fetal cir-
between day 8 and day 13, a monochori- culations. One twin is usually appropriate for gesta-
onic/monoamniotic pregnancy ensues (<5%); and if tional age (AGA) while the other twin is usually
the division occurs on or after day 13, incomplete sep- IUGR. The IUGR twin is typically in the oligohy-
aration (conjoined twins) is the rule (<0.5%). Chori- dramniotic sac and is compressed against one edge of
onicity correlates directly with perinatal mortality, the uterus, also known as the “stuck twin” syn-
which is especially high with monochori- drome.172 Following delivery, a difference in birth
onic/monoamniotic twins (65%-70%). Chorionicity weight of ≥20% or a difference in hematocrit of ≥5
is determined most accurately by examination of the g/dL confirms the diagnosis. The larger twin is often
membranes after delivery. Antenatal diagnosis is polycythemic while the IUGR twin is anemic. Prog-
more difficult.159-161 Typically, ultrasound examination nosis depends on gestational age, severity, and under-
in the first half of the pregnancy can be performed to lying etiology. Overall perinatal mortality is 40%-
evaluate the point at which the amniotic/chorionic 80%.173, 174 Treatment options include expectant man-
membranes arise from the placenta to determine if the agement, serial amniocentesis of the polyhydramni-
fetuses are dichorionic (twin peak or lamda sign) or otic sac, indomethacin (to decrease fetal urine output),

236 OBSTETRICS AND GYNECOLOGY—2009


laser obliteration of the placental vascular communi- are several management considerations specific to
cations or selective fetal reduction.175-178 multiple gestation, outlined below.

Management Multifetal Pregnancy Reduction

Gravidas with multiple gestations should be coun- Overall, 10%-15% of higher-order multiple pregnan-
seled about the increased risk of preeclampsia, cies (triplets and up) will reduce spontaneously dur-
preterm labor, postpartum hemorrhage, anemia, fetal ing the first trimester.164 If not, the option of multifetal
loss, fetal anomalies, IUGR, and cesarean delivery. pregnancy reduction to twins at 13-15 weeks should
Principles of management include early diagnosis, be discussed. The benefits of reduction include
screening for fetal anomalies, determination of chori- increased length of gestation, increased birth weight,
onicity, and regular antepartum follow-up (serial and reduced prematurity and perinatal mortality and
ultrasound for growth at least every 3-4 weeks to mortality.164, 181-183 The procedure-related loss rate prior
screen for discordant growth).179 Maternal serum to 20 weeks may be as high as 15% (range: 5%-35%),
alpha-fetoprotein (MS-AFP) screening for multiple which is comparable to the background risk for
gestation is a reliable screen for neural tube defects; higher-order multiple pregnancies.164, 182-185 However,
however, serum biochemical marker screening for the fetal loss rate increases with advancing gestation
aneuploidy in the presence of more than one fetus is at the time of the reduction. Multifetal pregnancy
not particularly reliable, due to the inherent structure reduction should be distinguished from selective fetal
of the test parameters.180 Maternal plasma volume is reduction, in which one fetus is selectively terminated
increased by 100%-200% with multiple gestation, because of a known structural or chromosomal
placing the gravida at higher risk for anemia. Addi- abnormality.186, 187
tional folate and iron supplementation should be con-
sidered in multiple gestation. Multifetal pregnancies
are at higher risk for cesarean delivery. Patients should
Screening for Congenital Anomalies

be counseled about labor analgesia and anesthesia, the Using twin populations, maternal serum alpha-feto
possible need for emergent delivery, and the need for protein (MS-AFP) and “quadruple panel” screening
multiple pediatric teams in the delivery room. There (MS-AFP, estriol, hCG and activin A) has been stan-

Table 12

Complications of Multiple Pregnancy

Maternal complications Uteroplacental complications Fetal complications

Anemia Placenta previa Fetal growth discordance

Hyperemesis gravidarum Preterm PROM IUGR

Gestational diabetes Cord entanglement IUFD of one or both twins

Preterm labor Postpartum hemorrhage Congenital anomalies

Cesarean delivery Twin-to-twin transfusion syndrome

CHAPTER 9: OBSTETRIC COMPLICATIONS 237


8. Premature Rupture
of Membranes

dardized for twins as it is for singletons at 15-20 PROM refers to rupture of the fetal membranes prior
weeks.188, 189 In dizygous pregnancies, the risk of aneu- to the onset of uterine contractions.198 It can be clas-
ploidy (genetic abnormality) is independent for each sified as term PROM (≥37 weeks) or preterm PROM
fetus. As such, the chance that 1 or both fetuses have a (<37 weeks). Latency (the time interval between
karyotypic abnormality is greater than for a singleton. PROM and delivery) is dependent on several factors:
Amniocentesis is recommended when the probability (1.) gestational age (at term, 50% of women with
of aneuploidy is equal to or greater than the proce- PROM will go into spontaneous labor within 12 hours
dure-related pregnancy loss rate (estimated at 1 in and 95% within 72 hours; latency is generally longer
270).190, 191 In singleton pregnancies, this balance is if PROM occurs preterm with 50% of women going
reached at a maternal age at delivery of 35 years. In into labor within 24-48 hours and 70%-90% within 7
twin pregnancies, amniocentesis should be offered to days)199; (2.) severity of oligohydramnios (severe
women at approximately 32 years of age.192, 193 oligohydramnios is associated with shortened latency
period );200 and (3.) number of fetuses (twins have a
Route of Delivery shorter latency period than singletons).201

The recommended route of delivery of twins depends


on presentation, gestational age (or EFW), concor-
Diagnosis

dance, and maternal and fetal well-being. Prior PROM is a clinical diagnosis with evidence of vaginal
cesarean is not an absolute contraindication to vaginal pooling of amniotic fluid on sterile speculum exami-
delivery of twins.194 Breech extraction of a nonvertex, nation, which is alkaline (vaginal fluid turns yellow
concordant second twin is a safe procedure,195, 196 but nitrazine paper blue) and demonstrates “ferning”
should only be performed by an experienced obstetric (microscopic crystallization) on drying. Evidence of
care provider. Preparation for a possible breech diminished amniotic fluid volume on ultrasound may
extraction should include an ultrasound machine to help to confirm the diagnosis, but is not a prerequisite
assist in evaluation of fetal heart rate and presentation, for the diagnosis. Sometimes a gush of fluid can be
specialized forceps to assist in delivery of the after- observed to emanate from the cervix when a patient
coming head (Piper forceps), an experienced anesthe- coughs during a speculum exam. The fluid should also
siologist and a uterine relaxant, such as intravenous be categorized as clear, blood-tinged, or meconium-
nitroglycerin or halothane by mask. Cesarean delivery stained. Differential diagnosis includes leakage of
has traditionally been recommended for multiple urine and vaginal discharge. If equivocal, an amnio-
pregnancies in which the presenting fetus is not vertex centesis can be performed with instillation of indigo
and for all higher-order multiple pregnancies, carmine dye into the amniotic cavity (“amnio-dye
although vaginal delivery may be appropriate in test”). Leakage of the dye into the vagina as evidenced
selected patients.197 by staining of a tampon within 15-20 minutes will
confirm the diagnosis. The patient should be advised
that, after an hour or so, her urine may also stain blue.

Term PROM

Rupture of the membranes is a normal physiologic


event at term. Rupture of membranes at term prior to
the onset of uterine contractions (term PROM) occurs
in 8%-10% of term pregnancies.202 Contraindications
to expectant management in the setting of term
PROM include intra-amniotic infection, non-reassur-
ing fetal testing, vaginal bleeding and active labor. In
the absence of such contraindications, both expectant
management and immediate augmentation of labor
are acceptable options.203 Severe oligohydramnios
may be associated with umbilical cord compression in

238 OBSTETRICS AND GYNECOLOGY—2009


labor leading to non-reassuring fetal testing and amniotic infection. Patients should be placed on
cesarean delivery. In this setting, amnioinfusion with pelvic rest (no tampons, no douching, no sexual inter-
saline has been shown to decrease the risk of cesarean course). A screening sonogram should be performed
for non-reassuring fetal testing (but has not necessar- to determine fetal presentation as non-vertex presen-
ily been shown to improve perinatal outcome). tation places the fetus at risk for umbilical cord pro-
lapse. Hospitalization, bed rest and fetal surveillance
have been the mainstay of management of preterm
PROM.204 Areas of controversy in the management of
Preterm PROM

Preterm PROM complicates 2%-4% of singleton and preterm PROM include:


7%-10% of twin pregnancies. It is associated with
30%-40% of preterm births and 10% of all perinatal 1.) Tocolysis. Preterm PROM is a relative contraindi-
mortality.204 Risk factors include prior preterm PROM, cation to tocolysis to prevent undue exposure of
unexplained vaginal bleeding, placental abruption fetuses to infected in utero environment, with subse-
(seen in 10%-15% of women with preterm PROM, quent postnatal risk of neurologic injury and cerebral
but may be a result rather than a cause),205 cervical palsy.207 Tocolytic agents may delay delivery by 24-48
insufficiency, vaginal or intra-amniotic infection, hours in the setting of intact membranes, but do not
amniocentesis, smoking, multiple pregnancy, polyhy- appear to delay delivery or improve perinatal out-
dramnios, chronic steroid treatment, connective tissue come in pregnancies complicated by preterm
diseases (systemic lupus erythematosus, Ehlers-Dan- PROM.204
los syndrome), anemia, low socioeconomic status and
unmarried marital status. Factors which are not associ- 2.) Antibiotics. Prophylactic broad-spectrum antibi-
ated with preterm PROM include coitus, cervical otic therapy has consistently been shown to prolong
examinations, maternal exercise and parity. The recur- latency in the setting of preterm PROM,208, 209 and this
rence risk is 20%-30%.204 appears to translate into an improvement in perinatal
outcome. There is currently no evidence to recom-
Complications mend 1 antibiotic regimen over another. The most
Neonatal complications are related primarily to pre- commonly used antibiotic regimen is ampicillin and
maturity, including RDS, IVH, sepsis, pulmonary erythromycin for 7 days.
hypoplasia (especially with preterm PROM <22
weeks) and skeletal deformities/limb strictures 3.) Antenatal corticosteroids. A single course of
(related to severity and duration of preterm PROM). antenatal glucocorticoids is recommended for all
Overall, preterm PROM is associated with a 4-fold pregnancies at high risk of delivering before 34 weeks
increase in perinatal mortality and a 3-fold increase in gestation with intact membranes and before 32 weeks
neonatal morbidity.204, 206 The fetus is at risk for devel- with preterm PROM with a view to decreasing the
oping chorioamnionitis, stillbirth from cord accident incidence of RDS, IVH and NEC.68-70 The benefit of
or placental abruption, non-reassuring fetal heart rate antenatal corticosteroids in pregnancies complicated
tracings or precipitous delivery. Maternal complica- by preterm PROM at 32-34 weeks gestation is not
tions include increased rates of cesarean delivery, clear.70
intra-amniotic infection and postpartum endometritis.
4.) Fetal surveillance. Fetuses in pregnancies com-
Management plicated by preterm PROM are at risk for ascending
Management of preterm PROM should be individual- infection, cord accident, placental abruption and (pos-
ized. The risk of prematurity should be weighed sibly) uteroplacental insufficiency. Amniocentesis
against the risk of expectant management, primarily may be considered in the setting preterm PROM to
intra-amniotic infection.204, 206 Amniotic fluid can be test for evidence of intra-amniotic infection and to
used to assess fetal lung maturity by testing for the confirm fetal lung maturity with a view to affecting an
lethicin/sphingomyelin (L/S) ratio and presence of earlier delivery. In some cases, vaginal pooled amni-
phosphatidyl glycerol (PG). In the setting of expectant otic fluid can be aspirated and tested for fetal lung
management for preterm PROM, new onset uterine maturation. Loss of fetal breathing in the BPP was
contractions may portend the development of intra-

CHAPTER 9: OBSTETRIC COMPLICATIONS 239


9. Antepartum Hemorrhage

Antepartum hemorrhage is defined as vaginal bleed-


ing after 24 weeks gestation and before labor, and
previously hailed as an early sign of intrauterine infec- complicates 4%-5% of all pregnancies. Placenta pre-
tion, but more recent studies have refuted this idea.210 via (20%) and placental abruption (30%) are the most
In the absence of evidence of uteroplacental insuffi- common causes of antepartum hemorrhage. Other
ciency, fetal surveillance has not been demonstrated to causes include vasa previa, early labor and
reliably diagnose or predict intra-amniotic infection. lesions/lacerations of the lower genital tract.
Fetal surveillance should therefore be instituted only
for the usual obstetric indications, such as fetal non-
stress testing (NST) to assess for variable decelera-
Placenta Previa

tions in the setting of oligohydramnios. Placenta previa refers to implantation of the placenta
over the cervical os in advance of the fetal presenting
part, and complicates 1 in 200 pregnancies.211 Risk
factors include multiparity, advanced maternal age,
prior placenta previa, prior cesarean delivery and
smoking. Placenta previa may be asymptomatic or
may present clinically with painless, bright-red vagi-
nal bleeding. Fetal malpresentation due to the inability
of the presenting part to engage the pelvis may further
suggest the diagnosis. Placenta previa is primarily a
sonographic diagnosis. Transvaginal sonogram can be
safely performed in the setting of abnormal placenta-
tion to quantify the distance from the leading edge of
the placenta to the internal os of the cervix. If the lead-
ing edge of the placenta crosses the cervical os, a com-
plete previa is diagnosed. If the leading edge of the
placenta is within 2 cm of the cervical os, a marginal
previa is diagnosed.212 Low-lying placenta is defined
as a placenta with its leading edge between 2-3 cm
from the internal cervical os. As the lower uterine seg-
ment develops with advancing gestational age, the
leading edge of the placenta may appear to “move”
further from the internal os.213

Complications
Maternal complications include placenta accreta,
which refers to abnormal attachment of placental villi
to the uterine wall in which chorionic villi are directly
attached to the myometrium due to a poorly devel-
oped decidua basalis, and Nitabuch’s layer that nor-
mally separates the placenta from the uterine
myometrium.214 In the absence of placenta previa, pla-
centa accreta is rare (1 in 7000 pregnancies). How-
ever, it complicates 5%-15% of pregnancies with pla-
centa previa, 25% with previa and 1 prior cesarean,
and 60% with previa and 2 or more prior cesareans.215
Neonatal complications include preterm birth and
malpresentation. Fetal anemia may result from vasa
previa associated with a placenta previa, which is an
indication for an emergent delivery to prevent exsan-
guination of the fetus.216 Placenta previa is not associ-
ated with IUGR.217

240 OBSTETRICS AND GYNECOLOGY—2009


Management Complications. Maternal complications include mor-
The goal of antepartum management is to maximize tality (due to hemorrhage, cardiac failure or renal fail-
fetal maturation while minimizing risk to mother and ure [0.5%-5%]) and coagulopathy (10%). Fetal com-
fetus. Blind digital vaginal examination should be plications include IUFD in 10%-35% of cases due pri-
avoided in all women with antepartum hemorrhage marily to fetal hypoxia, exsanguination and/or com-
until placenta previa is excluded. Non-reassuring plications of prematurity. Chronic abruption is also
fetal testing and excessive maternal hemorrhage are associated with an increased rate of congenital
contraindications to expectant management, and may anomalies and IUGR.219, 221
necessitate immediate cesarean delivery irrespective
of gestational age. However, most episodes of antena- Management. Hospitalization is indicated to evalu-
tal bleeding are not life-threatening. With careful ate maternal and fetal condition. Mode and timing
monitoring, delivery can be safely delayed in most of delivery depends on the condition of the mother
cases. Placenta previa may resolve with time due to and fetus, and on gestational age. In the setting of
cephalic growth of the lower uterine segment, draw- hemodynamic instability, invasive monitoring and
ing the leading edge of the placenta away from the immediate delivery may be necessary. If the abrup-
internal os, thereby allowing vaginal delivery to pro- tion is mild and pregnancy is remote from term,
ceed. Indeed, only 5% of low-lying placentae iden- expectant management may be appropriate. Placen-
tified by ultrasound at 14-20 weeks gestation persist to tal abruption is a relative contraindication to tocoly-
term (although complete placenta previa is unlikely to sis, particularly with beta-agonists that may cause
resolve).218 Cesarean delivery is generally performed maternal tachycardia and increased pulse pressure
by 37 weeks gestation due to active maternal hemor- to the site of the abruption. The risk of cesarean
rhage or concern over impending risk of maternal delivery is increased primarily due to fetal
hemorrhage. If elective delivery of an asymptomatic compromise.
patient is planned prior to 39 weeks gestation, it
should be done only after documentation of fetal lung
maturity.
Vasa Previa

Vasa previa refers to the presence of fetal vessels


coursing through the membranes (velamentous inser-
tion) overlying the internal os ahead of presenting part
Placental Abruption

Placental abruption refers to premature separation of of the fetus. Vasa previa is usually asymptomatic, but
the placenta from the underlying maternal decidua, may present with painless bright-red vaginal bleed-
and complicates 1 in 120 pregnancies.219, 220 Risk fac- ing, often associated with diminished fetal movement.
tors include hypertension, prior placental abruption, Since bleeding is from the umbilical vessels and is
trauma, smoking, cocaine, uterine anomaly or fetal in origin, fetal mortality is >75%, due primarily
fibroids, multiparity, advanced maternal age, preterm to fetal exsanguination. Diagnosis is by the bedside
PROM, bleeding diathesis and an overdistended Apt test (hemoglobin alkaline denaturation test),
uterus (multifetal gestations, polyhydramnios).220 Pla- which involves adding 2-3 drops of an alkaline solu-
cental abruption is a clinical diagnosis that may tion (NaOH) to 1 mL of blood. If the blood is mater-
include vaginal bleeding (80%), painful uterine con- nal, erythrocytes will rupture and the mixture will turn
tractions (35%), and abdominal tenderness (70%), brown. Fetal erythrocytes, on the other hand, are resis-
with or without non-reassuring fetal testing (50%). tant to rupture and the mixture will remain red. Emer-
The amount of vaginal bleeding is not a reliable indi- gent cesarean delivery is indicated regardless of gesta-
cator of the severity of the condition, because bleed- tional age if the fetus is viable. Brisk vaginal bleeding
ing may be concealed. A retroplacental collection of temporally related to spontaneous or artificial rupture
≥300 mL is necessary for sonographic visualization, of the membranes, particularly in light of a placenta
and only 2% of placental abruptions can be visualized previa or low-lying placenta, and acute changes in
on ultrasound. Serial measurements of fundal height fetal heart rate tracing, should prompt consideration of
and abdominal girth are useful to monitor large retro- this diagnosis.222
placental blood collections.

CHAPTER 9: OBSTETRIC COMPLICATIONS 241


10. References

1. Shortle B, Jewelewicz R. Cervical 11. Rush RW, Isaacs S, McPherson K, Jones L,


incompetence. Fertil Steril. 1989;52(2):181-188. Chalmers I, Grant A. A randomized controlled
trial of cervical cerclage in women at high risk of
2. ACOG Practice Bulletin. Cervical insufficiency. spontaneous preterm delivery. Br J Obstet
Obstet Gynecol. 2003;102(5 Pt 1):1091-1099. Gynaecol. 1984;91(8):724-730.

3. Harger JH. Cervical cerclage: patient selection, 12. Roman AS, Rebarber A, Pereira L, Sfakianaki
morbidity, and success rates. Clin Perinatol. AK, Mulholland J, Berghella V. The efficacy of
1983;10(2):321-341. sonographically indicated cerclage in multiple
gestations. J Ultrasound Med. 2005;24(6):763-
4. Golan A, Barnan R, Wexler S, Langer R, 768; quiz 70-71.
Bukovsky I, David MP. Incompetence of the
uterine cervix. Obstet Gynecol Surv. 13. To MS, Alfirevic Z, Heath VC, et al. Cervical
1989;44(2):96-107. cerclage for prevention of preterm delivery in
women with short cervix: randomised controlled
5. ACOG Practice Bulletin. Clinical management trial. Lancet. 2004;363(9424):1849-1853.
guidelines for obstetrician-gynecologist. Num-
ber 43, May 2003. Management of preterm 14. Mays JK, Figueroa R, Shah J, Khakoo H,
labor. Obstet Gynecol. 2003;101(5 Pt 1): Kaminsky S, Tejani N. Amniocentesis for selec-
1039-1047. tion before rescue cerclage. Obstet Gynecol.
2000;95(5):652-655.
6. Norman JE. Cervical function and prematurity.
Best Pract Res Clin Obstet Gynaecol. May 15. Romero R, Gonzalez R, Sepulveda W, et al.
2007. Infection and labor. VIII. Microbial invasion of
the amniotic cavity in patients with suspected
7. Althuisius SM, Dekker GA. A five century evo- cervical incompetence: prevalence and clinical
lution of cervical incompetence as a clinical significance. Am J Obstet Gynecol. 1992;167(4 :
entity. Curr Pharm Des. 2005;11(6):687-697. 1):1086-1091.

8. Althuisius SM, Dekker GA, Hummel P, 16. MacDougall J, Siddle N. Emergency cervical
Bekedam DJ, van Geijn HP. Final results of the cerclage. Br J Obstet Gynaecol.
Cervical Incompetence Prevention Randomized 1991;98(12):1234-1238.
Cerclage Trial (CIPRACT): therapeutic cer-
clage with bed rest versus bed rest alone. Am J 17. Olatunbosun OA, Dyck F. Cervical cerclage
Obstet Gynecol. 2001;185(5):1106-1112. operation for a dilated cervix. Obstet Gynecol.
1981;57(2):166-170.
9. Dor J, Shalev J, Mashiach S, Blankstein J, Serr
DM. Elective cervical suture of twin pregnan- 18. Scheerer LJ, Lam F, Bartolucci L, Katz M. A
cies diagnosed ultrasonically in the first new technique for reduction of prolapsed fetal
trimester following induced ovulation. Gynecol membranes for emergency cervical cerclage.
Obstet Invest. 1982;13(1):55-60. Obstet Gynecol. 1989;74(3:1):408-410.

10. Lazar P, Gueguen S, Dreyfus J, Renaud R, Pon- 19. Sher G. Congenital incompetence of the cervical
tonnier G, Papiernik E. Multicentred controlled os: reduction of bulging membranes with a mod-
trial of cervical cerclage in women at moderate ified Foley catheter. J Reprod Med.
risk of preterm delivery. Br J Obstet Gynaecol. 1979;22(3):165-167.
1984;91(8):731-735.

242 OBSTETRICS AND GYNECOLOGY—2009


20. McDonald IA. Suture of the cervix for 30. McElrath TF, Norwitz ER, Lieberman ES,
inevitable miscarriage. J Obstet Gynaecol Br Heffner LJ. Management of cervical cerclage
Emp. 1957;64(3):346-350. and preterm premature rupture of the mem-
branes: should the stitch be removed? Am J
21. Goodlin RC. Cervical incompetence, hourglass Obstet Gynecol. 2000;183(4):840-846.
membranes, and amniocentesis. Obstet
Gynecol. 1979;54(6):748-750. 31. Jenkins TM, Berghella V, Shlossman PA, et al.
Timing of cerclage removal after preterm pre-
22. Ochi M, Ishikawa K, Itoh H, et al. [Aggressive mature rupture of membranes: maternal and
management of prolapsed fetal membranes ear- neonatal outcomes. Am J Obstet Gynecol.
lier than 26 weeks gestation by emergent 2000;183(4):847-852.
McDonald cerclage combined with amniocente-
sis and bladder overfilling]. Nippon Sanka 32. Final report of the Medical Research Coun-
Fujinka Gakkai Zasshi. 1994;46(4):301-307. cil/Royal College of Obstetricians and Gynae-
cologists multicentre randomised trial of cervi-
23. Locatelli A, Vergani P, Bellini P, Strobelt N, cal cerclage. MRC/RCOG Working Party on
Arreghini A, Ghidini A. Amnioreduction in Cervical Cerclage. Br J Obstet Gynaecol.
emergency cerclage with prolapsed membranes: 1993;100(6):516-523.
comparison of two methods for reducing the
membranes. Am J Perinatol. 1999;16(2):73-77. Preterm Labor

24. Daskalakis G, Papantoniou N, Mesogitis S, 33. Rush RW, Keirse MJ, Howat P, Baum JD,
Antsaklis A. Management of cervical insuffi- Anderson AB, Turnbull AC. Contribution of
ciency and bulging fetal membranes. Obstet preterm delivery to perinatal mortality. Br Med
Gynecol. 2006;107(2 Pt 1):221-226. J. 1976;2(6042):965-968.

25. Rozenberg P, Senat MV, Gillet A, Ville Y. Com- 34. Ananth CV, Vintzileos AM. Epidemiology of
parison of two methods of cervical cerclage by preterm birth and its clinical subtypes. J Matern
ultrasound cervical measurement. J Matern Fetal Neonatal Med. 2006;19(12):773-82.
Fetal Neonatal Med. 2003;13(5):314-317.
35. Norwitz ER, Robinson JN, Challis JR. The control
26. Iams JD. Abnormal Cervical Competence. 5th of labor. N Engl J Med. 1999;341(9):660-666.
ed. Philadelphia: Saunders; 2004.
36. Romero R, Avila C, Brekus CA, Morotti R. The
27. Shirodkar V. A new method of operative treat- role of systemic and intrauterine infection in
ment for habitual abortion in the second preterm parturition. Ann NY Acad Sci.
trimester of pregnancy. Antiseptic. 1955;52:299. 1991;622:355-375.

28. Benson RC, Durfee RB. Transabdominal cer- 37. Dudley DJ. Pre-term labor: an intra-uterine
vico uterine cerclage during pregnancy for the inflammatory response syndrome? J Reprod
treatment of cervical incompetency. Obstet Immunol. 1997;36(1-2):93-109.
Gynecol. 1965;25:145-155.
38. Creasy RK, Gummer BA, Liggins GC. System
29. Novy MJ. Transabdominal cervicoisthmic cer- for predicting spontaneous preterm birth. Obstet
clage: a reappraisal 25 years after its introduc- Gynecol. 1980;55(6):692-695.
tion. Am J Obstet Gynecol. 1991;164(6:1):1635-
1641; discussion 41-42. 39. Mercer BM, Goldenberg RL, Das A, et al. The
preterm prediction study: a clinical risk assess-
ment system. Am J Obstet Gynecol.
1996;174(6):1885-1893; discussion 93-95.

CHAPTER 9: OBSTETRIC COMPLICATIONS 243


40. Iams JD, Johnson FF, O’Shaughnessy RW. A 49. Goodwin TM. A role for estriol in human labor,
prospective random trial of home uterine activ- term and preterm. Am J Obstet Gynecol.
ity monitoring in pregnancies at increased risk of 1999;180(1 Pt 3):S208-S213.
preterm labor. Part II. Am J Obstet Gynecol.
1988;159(3):595-603. 50. McGregor JA, Jackson GM, Lachelin GC, et al.
Salivary estriol as risk assessment for preterm
41. Mortensen OA, Franklin J, Lofstrand T, Svan- labor: a prospective trial. Am J Obstet Gynecol.
berg B. Prediction of preterm birth. Acta Obstet 1995;173(4):1337-1342.
Gynecol Scand. 1987;66(6):507-512.
51. Goldenberg RL, Cliver SP, Bronstein J, Cutter
42. Iams JD, Goldenberg RL, Meis PJ, et al. The GR, Andrews WW, Mennemeyer ST. Bed rest in
length of the cervix and the risk of spontaneous pregnancy. Obstet Gynecol. 1994;84(1):131-
premature delivery. National Institute of Child 136.
Health and Human Development Maternal Fetal
Medicine Unit Network. N Engl J Med. 52. Besinger RE, Niebyl JR. The safety and efficacy
1996;334(9):567-572. of tocolytic agents for the treatment of preterm
labor. Obstet Gynecol Surv. 1990;45(7):415-
43. Heath VC, Southall TR, Souka AP, Elisseou A, 440.
Nicolaides KH. Cervical length at 23 weeks of
gestation: prediction of spontaneous preterm 53. Higby K, Xenakis EM, Pauerstein CJ. Do
delivery. Ultrasound Obstet Gynecol. tocolytic agents stop preterm labor? A critical
1998;12(5):312-317. and comprehensive review of efficacy and
safety. Am J Obstet Gynecol. 1993;168(4):1247-
44. Hillier SL, Nugent RP, Eschenbach DA, et al. 1256; discussion 56-59.
Association between bacterial vaginosis and
preterm delivery of a low-birth-weight infant. 54. Hill WC. Risks and complications of tocolysis.
The Vaginal Infections and Prematurity Study Clin Obstet Gynecol. 1995;38(4):725-745.
Group. N Engl J Med. 1995;333(26):1737-1742.
55. Hollander DI, Nagey DA, Pupkin MJ. Magne-
45. Gibbs RS, Romero R, Hillier SL, Eschenbach sium sulfate and ritodrine hydrochloride: a ran-
DA, Sweet RL. A review of premature birth and domized comparison. Am J Obstet Gynecol.
subclinical infection. Am J Obstet Gynecol. 1987;156(3):631-637.
1992;166(5):1515-1528.
56. Witlin AG, Sibai BM. Magnesium sulfate ther-
46. Lockwood CJ, Senyei AE, Dische MR, et al. apy in preeclampsia and eclampsia. Obstet
Fetal fibronectin in cervical and vaginal secre- Gynecol. 1998;92(5):883-889.
tions as a predictor of preterm delivery. N Engl J
Med. 1991;325(10):669-674. 57. Lamm CI, Norton KI, Murphy RJ, Wilkins IA,
Rabinowitz JG. Congenital rickets associated
47. Goldenberg RL, Mercer BM, Meis PJ, Copper with magnesium sulfate infusion for tocolysis. J
RL, Das A, McNellis D. The preterm prediction Pediatr. 1988;113(6):1078-1082.
study: fetal fibronectin testing and spontaneous
preterm birth. NICHD Maternal Fetal Medicine 58. Faidley CK, Dix PM, Morgan MA, Schechter E.
Units Network. Obstet Gynecol. Electrocardiographic abnormalities during rito-
1996;87(5:1):643-648. drine administration. South Med J.
1990;83(5):503-506.
48. Iams JD, Casal D, McGregor JA, et al. Fetal
fibronectin improves the accuracy of diagnosis
of preterm labor. Am J Obstet Gynecol.
1995;173(1):141-145.

244 OBSTETRICS AND GYNECOLOGY—2009


59. Peterson A, Peterson K, Tongen S, et al. Glucose 68. Effect of corticosteroids for fetal maturation on
intolerance as a consequence of oral terbutaline perinatal outcomes. NIH Consensus Develop-
treatment for preterm labor. J Fam Pract. ment Panel on the Effect of Corticosteroids for
1993;36(1):25-31. Fetal Maturation on Perinatal Outcomes. JAMA.
1995;273(5):413-418.
60. Vanhaesebrouck P, Thiery M, Leroy JG, et al.
Oligohydramnios, renal insufficiency, and ileal 69. ACOG committee opinion. Antenatal corticos-
perforation in preterm infants after intrauterine teroid therapy for fetal maturation. Number
exposure to indomethacin. J Pediatr. 147—December 1994. Committee on Obstetric
1988;113(4):738-743. Practice. American College of Obstetricians and
Gynecologists. Int J Gynaecol Obstet.
61. Wiggins DA, Elliott JP. Oligohydramnios in 1995;48(3):340-342.
each sac of a triplet gestation caused by
Motrin®—fulfilling Kock’s postulates. Am J 70. Lee MJ, Davies J, Guinn D, et al. Single versus
Obstet Gynecol. 1990;162(2):460-461. weekly courses of antenatal corticosteroids in
preterm premature rupture of membranes.
62. Suarez VR, Thompson LL, Jain V, et al. The Obstet Gynecol. 2004;103(2):274-281.
effect of in utero exposure to indomethacin on
the need for surgical closure of a patent ductus 71. Committee on Obstetric P. ACOG committee
arteriosus in the neonate. Am J Obstet Gynecol. opinion: antenatal corticosteroid therapy for
2002;187(4):886-888. fetal maturation. Obstet Gynecol.
2002;99(5:1):871-873.
63. Itabashi K, Ohno T, Nishida H. Indomethacin
responsiveness of patent ductus arteriosus and 72. Vermillion ST, Soper DE, Bland ML, Newman
renal abnormalities in preterm infants treated RB. Effectiveness of antenatal corticosteroid
with indomethacin. J Pediatr. 2003;143(2): administration after preterm premature rupture
203-207. of the membranes. Am J Obstet Gynecol.
2000;183(4):925-929.
64. van Veen AJ, Pelinck MJ, van Pampus MG,
Erwich JJ. Severe hypotension and fetal death 73. Rust OA, Bofill JA, Arriola RM, Andrew ME,
due to tocolysis with nifedipine. BJOG. Morrison JC. The clinical efficacy of oral
2005;112(4):509-510. tocolytic therapy. Am J Obstet Gynecol.
1996;175(4 Pt 1):838-842.
65. Parasuraman R, Gandhi MM, Liversedge NH.
Nifedipine tocolysis associated atrial fibrillation 74. Guinn DA, Goepfert AR, Owen J, Wenstrom
responds to DC cardioversion. BJOG. KD, Hauth JC. Terbutaline pump maintenance
2006;113(7):844-845. therapy for prevention of preterm delivery: a
double-blind trial. Am J Obstet Gynecol.
66. Al-Omari WR, Al-Shammaa HB, Al-Tikriti 1998;179(4):874-878.
EM, Ahmed KW. Atosiban and nifedipine in
acute tocolysis: a comparative study. Eur J 75. Ogburn PL Jr, Julian TM, Williams PP, Thomp-
Obstet Gynecol Reprod Biol. 2006;128 son TR. The use of magnesium sulfate for tocol-
(1-2):129-134. ysis in preterm labor complicated by twin gesta-
tion and betamimetic-induced pulmonary
67. Stika CS, Gross GA, Leguizamon G, et al. A edema. Acta Obstet Gynecol Scand.
prospective randomized safety trial of celecoxib 1986;65(7):793-794.
for treatment of preterm labor. Am J Obstet
Gynecol. 2002;187(3):653-660.

CHAPTER 9: OBSTETRIC COMPLICATIONS 245


76. Ferguson JE, 2nd, Hensleigh PA, Kredenster D. 86. Rosen MG, Dickinson JC. Management of post-
Adjunctive use of magnesium sulfate with rito- term pregnancy. N Engl J Med.
drine for preterm labor tocolysis. Am J Obstet 1992;326(24):1628-1629.
Gynecol. 1984;148(2):166-171.
87. Rand L, Robinson JN, Economy KE, Norwitz
77. Valenzuela G, Cline S. Use of magnesium sul- ER. Post-term induction of labor revisited.
fate in premature labor that fails to respond to Obstet Gynecol. 2000;96(5:1):779-783.
betamimetic drugs. Am J Obstet Gynecol.
1982;143(6):718-719. 88. Alexander JM, McIntire DD, Leveno KJ. Forty
weeks and beyond: pregnancy outcomes by
78. Gibbs RS, Eschenbach DA. Use of antibiotics to week of gestation. Obstet Gynecol.
prevent preterm birth. Am J Obstet Gynecol. 2000;96(2):291-294.
1997;177(2):375-380.
89. Treger M, Hallak M, Silberstein T, Friger M,
Katz M, Mazor M. Post-term pregnancy: should
induction of labor be considered before 42
Post-term Pregnancy

79. ACOG Practice Bulletin. Clinical management weeks? J Matern Fetal Neonatal Med.
guidelines for obstetricians-gynecologists. 2002;11(1):50-53.
Number 55, September 2004 (replaces practice
pattern number 6, October 1997). Management 90. American College of Obstetricians and Gynecol-
of Postterm Pregnancy. Obstet Gynecol. ogists. ACOG Practice Bulletin No. 10. Induc-
2004;104(3):639-646. tion of Labor. Washington, DC:ACOG, 1999.

80. ACOG criteria set. Postterm pregnancy. Number 91. Crowley P. Interventions for preventing or
10—August 1995. Committee on Quality improving the outcome of delivery at or beyond
Assessment. American College of Obstetricians term. Cochrane Database Syst Rev.
and Gynecologists. Int J Gynaecol Obstet. 2000(2):CD000170.
1996;53(1):89-90.
92. Hannah ME, Hannah WJ, Hellmann J, Hewson
81. Barnes AC. Postmaturity syndrome; the obstetri- S, Milner R, Willan A. Induction of labor as
cian’s role in management. Calif Med. compared with serial antenatal monitoring in
1956;85(5):289-292. post-term pregnancy. A randomized controlled
trial. The Canadian Multicenter Post-term Preg-
82. Clifford SH. Postmaturity clinical syndrome and nancy Trial Group. N Engl J Med.
pathologic findings. AMA Am J Dis Child. 1992;326(24):1587-1592.
1953;86(3):319-321.
93. A clinical trial of induction of labor versus
83. Feldman GB. Prospective risk of stillbirth. expectant management in postterm pregnancy.
Obstet Gynecol. 1992;79(4):547-553. The National Institute of Child Health and
Human Development Network of Maternal-
84. American College of Obstetricians and Gynecol- Fetal Medicine Units. Am J Obstet Gynecol.
ogists. ACOG Practice Bulletin No. 22. Fetal 1994;170(3):716-723.
Macrosomia. Washington, DC:ACOG, 2000.

85. Spellacy WN, Miller S, Winegar A, Peterson


PQ. Macrosomia—maternal characteristics and
infant complications. Obstet Gynecol.
1985;66(2):158-161.

246 OBSTETRICS AND GYNECOLOGY—2009


104. Meekins JW, Pijnenborg R, Hanssens M,
McFadyen IR, van Asshe A. A study of placental
Hypertensive Disorders of Pregnancy

94. Rochat RW, Koonin LM, Atrash HK, Jewett JF. bed spiral arteries and trophoblast invasion in
Maternal mortality in the United States: report normal and severe pre-eclamptic pregnancies.
from the Maternal Mortality Collaborative. Br J Obstet Gynaecol. 1994;101(8):669-674.
Obstet Gynecol. 1988;72(1):91-97.
105. Brosens IA, Robertson WB, Dixon HG. The role
95. Berg CJ, Atrash HK, Koonin LM, Tucker M. of the spiral arteries in the pathogenesis of
Pregnancy-related mortality in the United preeclampsia. Obstet Gynecol Annu.
States, 1987-1990. Obstet Gynecol. 1972;1:177-191.
1996;88(2):161-167.
106. Cross JC, Werb Z, Fisher SJ. Implantation and
96. Lin CC, Lindheimer MD, River P, Moawad AH. the placenta: key pieces of the development puz-
Fetal outcome in hypertensive disorders of preg- zle. Science. 1994;266(5190):1508-1518.
nancy. Am J Obstet Gynecol. 1982;142(3):255-
260. 107. Maynard SE, Min JY, Merchan J, et al. Excess
placental soluble fms-like tyrosine kinase 1
97. Barr M, Jr. Teratogen update: angiotensin-con- (sFlt1) may contribute to endothelial dysfunc-
verting enzyme inhibitors. Teratology. tion, hypertension, and proteinuria in
1994;50(6):399-409. preeclampsia. J Clin Invest. 2003;111(5):649-
658.
98. Quan A. Fetopathy associated with exposure to
angiotensin converting enzyme inhibitors and 108. Thadhani R, Mutter WP, Wolf M, et al. First
angiotensin receptor antagonists. Early Hum trimester placental growth factor and soluble
Dev. 2006;82(1):23-28. fms-like tyrosine kinase 1 and risk for
preeclampsia. J Clin Endocrinol Metab.
99. Fretts RC. Etiology and prevention of stillbirth. 2004;89(2):770-775.
Am J Obstet Gynecol. 2005;193(6):1923-1935.
109. Report of the National High Blood Pressure
100. ACOG Practice Bulletin. Chronic hypertension Education Program Working Group on High
in pregnancy. ACOG Committee on Practice Blood Pressure in Pregnancy. Am J Obstet
Bulletins. Obstet Gynecol. 2001;98(1) suppl Gynecol. 2000;183(1):S1-S22.
177-185.
110. Odendaal HJ, Pattinson RC, Bam R, Grove D,
101. ACOG Practice Bulletin. Diagnosis and man- Kotze TJ. Aggressive or expectant management
agement of preeclampsia and eclampsia. Num- for patients with severe preeclampsia between
ber 33, January 2002. American College of 28-34 weeks gestation: a randomized controlled
Obstetricians and Gynecologists. Int J Gynaecol trial. Obstet Gynecol. 1990;76(6):1070-1075.
Obstet. 2002;77(1):67-75.
111. Sibai BM, Mercer BM, Schiff E, Friedman SA.
102. Dekker GA, Sibai BM. Etiology and pathogene- Aggressive versus expectant management of
sis of preeclampsia: current concepts. Am J severe preeclampsia at 28 to 32 weeks gestation:
Obstet Gynecol. 1998;179(5):1359-1375. a randomized controlled trial. Am J Obstet
Gynecol. 1994;171(3):818-822.
103. Redman CW, Sacks GP, Sargent IL. Preeclamp-
sia: an excessive maternal inflammatory 112. Alexander JM, Bloom SL, McIntire DD, Leveno
response to pregnancy. Am J Obstet Gynecol. KJ. Severe preeclampsia and the very low birth
1999;180(2:1):499-506. weight infant: is induction of labor harmful?
Obstet Gynecol. 1999;93(4):485-488.

CHAPTER 9: OBSTETRIC COMPLICATIONS 247


113. Nassar AH, Adra AM, Chakhtoura N, Gomez- 123. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe
Marin O, Beydoun S. Severe preeclampsia preeclampsia-eclampsia in young primigravid
remote from term: labor induction or elective women: subsequent pregnancy outcome and
cesarean delivery? Am J Obstet Gynecol. remote prognosis. Am J Obstet Gynecol.
1998;179(5):1210-1213. 1986;155(5):1011-1016.

114. Sibai BM. Treatment of hypertension in preg- 124. Sibai BM. Prevention of preeclampsia: a big dis-
nant women. N Engl J Med. 1996;335(4): appointment. Am J Obstet Gynecol.
257-265. 1998;179(5):1275-1278.

115. Lindenstrom E, Boysen G, Nyboe J. Influence of 125. Norwitz ER, Robinson JN, Repke JT. Preven-
systolic and diastolic blood pressure on stroke tion of preeclampsia: is it possible? Clin Obstet
risk: a prospective observational study. Am J Gynecol. 1999;42(3):436-454.
Epidemiol. 1995;142(12):1279-1290.
126. Askie LM, Duley L, Henderson-Smart DJ,
116. Fontenot MT, Lewis DF, Frederick JB, et al. A Stewart LA. Antiplatelet agents for prevention
prospective randomized trial of magnesium sul- of pre-eclampsia: a meta-analysis of individual
fate in severe preeclampsia: use of diuresis as a patient data. Lancet. 2007;369(9575):1791-
clinical parameter to determine the duration of 1798.
postpartum therapy. Am J Obstet Gynecol.
2005;192(6):1788-1793; discussion 93-94. Intrauterine Fetal Demise

117. Which anticonvulsant for women with eclamp- 127. Spong CY, Erickson K, Willinger M, Hankins
sia? Evidence from the Collaborative Eclampsia GD, Schulkin J. Stillbirth in obstetric practice:
Trial. Lancet. 1995;345(8963):1455-1463. report of survey findings. J Matern Fetal
Neonatal Med. 2003;14(1):39-44.
118. Coetzee EJ, Dommisse J, Anthony J. A ran-
domised controlled trial of intravenous magne- 128. MacDorman MF, Hoyert DL, Martin JA, Mun-
sium sulphate versus placebo in the management son ML, Hamilton BE. Fetal and perinatal mor-
of women with severe pre-eclampsia. Br J tality, United States, 2003. Natl Vital Stat Rep.
Obstet Gynaecol. 1998;105(3):300-303. 2007;55(6):1-17.

119. Douglas KA, Redman CW. Eclampsia in the 129. Huang DY, Usher RH, Kramer MS, Yang H,
United Kingdom. BMJ. 1994;309(6966):1395- Morin L, Fretts RC. Determinants of unex-
1400. plained antepartum fetal deaths. Obstet Gynecol.
2000;95(2):215-221.
120. Sibai BM. Diagnosis, prevention, and manage-
ment of eclampsia. Obstet Gynecol. 130. Froen JF, Arnestad M, Frey K, Vege A, Saugstad
2005;105(2):402-410. OD, Stray-Pedersen B. Risk factors for sudden
intrauterine unexplained death: epidemiologic
121. Sibai BM, Villar MA, Mabie BC. Acute renal characteristics of singleton cases in Oslo, Nor-
failure in hypertensive disorders of pregnancy. way, 1986-1995. Am J Obstet Gynecol.
Pregnancy outcome and remote prognosis in 2001;184(4):694-702.
thirty-one consecutive cases. Am J Obstet
Gynecol. 1990;162(3):777-783. 131. Tenovuo A, Kero P, Piekkala P, Korvenranta H,
Erkkola R. Fetal and neonatal mortality of small-
122. Sibai BM. Chronic hypertension in pregnancy. for-gestational age infants. A 15-year study of
Obstet Gynecol. 2002;100(2):369-377. 381 cases. Eur J Pediatr. 1988;147(6):613-615.

248 OBSTETRICS AND GYNECOLOGY—2009


132. Spinillo A, Capuzzo E, Piazzi G, Nicola S, 142. Romero R, Duffy TP, Berkowitz RL, Chang E,
Colonna L, Iasci A. Maternal high-risk factors Hobbins JC. Prolongation of a preterm preg-
and severity of growth deficit in small for gesta- nancy complicated by death of a single twin in
tional age infants. Early Hum Dev. utero and disseminated intravascular coagula-
1994;38(1):35-43. tion. Effects of treatment with heparin. N Engl J
Med. 1984;310(12):772-774.
133. Wapner RJ, Lewis D. Genetics and metabolic
causes of stillbirth. Semin Perinatol. 143. Benirschke K. Intrauterine death of a twin:
2002;26(1):70-74. mechanisms, implications for surviving twin,
and placental pathology. Semin Diagn Pathol.
134. Kolialexi A, Tsangaris GT, Antsaklis A, 1993;10(3):222-231.
Mavroua A. Rapid clearance of fetal cells from
maternal circulation after delivery. Ann NY Acad 144. Szymonowicz W, Preston H, Yu VY. The surviv-
Sci. 2004;1022:113-118. ing monozygotic twin. Arch Dis Child.
1986;61(5):454-458.
135. Brookes JS, Hagmann C. MRI in fetal necropsy.
J Magn Reson Imaging. 2006;24(6):1221-1228. 145. Ben-Shlomo I, Alcalay M, Lipitz S, Leibowitz
K, Mashiach S, Barkai G. Twin pregnancies
136. Cernach MC, Patricio FR, Galera MF, Moron complicated by the death of one fetus. J Reprod
AF, Brunoni D. Evaluation of a protocol for Med. 1995;40(6):458-462.
postmortem examination of stillbirths and
neonatal deaths with congenital anomalies.
Pediatr Dev Pathol. 2004;7(4):335-341.
Intrauterine Growth Restriction

146. American College of Obstetricians and Gyne-


137. Reid DE, Weiner AE, Roby CC, Diamond LK. cologists. ACOG Practice Bulletin No. 12.
Maternal afibrinogenemia associated with long- Intrauterine growth restriction. Washington, DC:
standing intrauterine fetal death. Am J Obstet ACOG. 2000.
Gynecol. 1953;66(3):500-506.
147. Lin CC, Santolaya-Forgas J. Current concepts of
138. Pritchard JA. Fetal death in utero. Obstet fetal growth restriction: part I. Causes, classifica-
Gynecol. 1959;14:573-580. tion, and pathophysiology. Obstet Gynecol.
1998;92(6):1044-1055.
139. Carlson NJ, Towers CV. Multiple gestation com-
plicated by the death of one fetus. Obstet 148. Clausson B, Gardosi J, Francis A, Cnattingius S.
Gynecol. 1989;73(5:1):685-9. Perinatal outcome in SGA births defined by cus-
tomised versus population-based birthweight
140. D’Alton ME, Newton ER, Cetrulo CL. Intrauter- standards. Bjog. 2001;108(8):830-834.
ine fetal demise in multiple gestation. Acta
Genet Med Gemellol (Roma). 1984;33(1):43- 149. Pollack RN, Divon MY. Intrauterine growth
49. retardation: definition, classification, and etiol-
ogy. Clin Obstet Gynecol. 1992;35(1):99-107.
141. Bejar R, Vigliocco G, Gramajo H, et al. Antena-
tal origin of neurologic damage in newborn 150. Kazzi GM, Gross TL, Sokol RJ. Fetal biparietal
infants. II. Multiple gestations. Am J Obstet diameter and placental grade: predictors of
Gynecol. 1990;162(5):1230-1236. intrauterine growth retardation. Obstet Gynecol.
1983;62(6):755-759.

CHAPTER 9: OBSTETRIC COMPLICATIONS 249


151. Lin CC, Santolaya-Forgas J. Current concepts of 160. Winn HN, Gabrielli S, Reece EA, Roberts JA,
fetal growth restriction: part II. Diagnosis and Salafia C, Hobbins JC. Ultrasonographic criteria
management. Obstet Gynecol. 1999;93(1): for the prenatal diagnosis of placental chorionic-
140-146. ity in twin gestations. Am J Obstet Gynecol.
1989;161(6:1):1540-1542.
152. Lee MJ, Conner EL, Charafeddine L, Woods JR,
Jr., Priore GD. A critical birth weight and other 161. Scardo JA, Ellings JM, Newman RB. Prospec-
determinants of survival for infants with severe tive determination of chorionicity, amnionicity,
intrauterine growth restriction. Ann NY Acad Sci. and zygosity in twin gestations. Am J Obstet
2001;943:326-339. Gynecol. 1995;173(5):1376-1380.

153. Godfrey KM, Barker DJ. Fetal programming 162. Wood SL, St Onge R, Connors G, Elliot PD.
and adult health. Public Health Nutr. Evaluation of the twin peak or lambda sign in
2001;4(2B):611-624. determining chorionicity in multiple pregnancy.
Obstet Gynecol. 1996;88(1):6-9.
154. Odibo AO, Quinones JN, Lawrence-Cleary K,
Stamilio DM, Macones GA. What antepartum 163. Kovacs BW, Kirschbaum TH, Paul RH. Twin
fetal test should guide the timing of delivery of gestations: I. Antenatal care and complications.
the preterm growth-restricted fetus? A decision- Obstet Gynecol. 1989;74(3:1):313-317.
analysis. Am J Obstet Gynecol.
2004;191(4):1477-1482. 164. Haning RV, Jr., Seifer DB, Wheeler CA, Frish-
man GN, Silver H, Pierce DJ. Effects of fetal
155. Simchen MJ, Alkazaleh F, Adamson SL, et al. number and multifetal reduction on length of in
The fetal cardiovascular response to antenatal vitro fertilization pregnancies. Obstet Gynecol.
steroids in severe early-onset intrauterine 1996;87(6):964-968.
growth restriction. Am J Obstet Gynecol.
2004;190(2):296-304. 165. Hendricks CH. Twinning in relation to birth
weight, mortality, and congenital anomalies.
156. Mordel N, Ezra Y, Dorembus D, Benshushan A, Obstet Gynecol. 1966;27(1):47-53.
Schenker JG, Sadovsky E. Triplets are not so
rare any more. J Perinat Med. 1992;20(2):117- 166. Erkkola R, Ala-Mello S, Piiroinen O, Kero P,
122. Sillanpaa M. Growth discordancy in twin preg-
nancies: a risk factor not detected by measure-
ments of biparietal diameter. Obstet Gynecol.
1985;66(2):203-206.
Multiple Gestation

157. Norwitz E. Multiple Pregnancies: Trends past,


present and future. Philadelphia, PA: WB Saun- 167. Peek MJ, McCarthy A, Kyle P, Sepulveda W,
ders Company; 1998. Fisk NM. Medical amnioreduction with sulindac
to reduce cord complications in monoamniotic
158. Derom C, Vlietinck R, Derom R, Van den twins. Am J Obstet Gynecol. 1997;176(2):334-
Berghe H, Thiery M. Increased monozygotic 336.
twinning rate after ovulation induction. Lancet.
1987;1(8544):1236-1238. 168. Carr SR, Aronson MP, Coustan DR. Survival
rates of monoamniotic twins do not decrease
159. Barss VA, Benacerraf BR, Frigoletto FD, Jr. after 30 weeks gestation. Am J Obstet Gynecol.
Ultrasonographic determination of chorion type 1990;163(3):719-722.
in twin gestation. Obstet Gynecol.
1985;66(6):779-783. 169. Gonzalez MC, Reyes H, Arrese M, et al. Intra-
hepatic cholestasis of pregnancy in twin preg-
nancies. J Hepatol. 1989;9(1):84-90.

250 OBSTETRICS AND GYNECOLOGY—2009


170. Fick AL, Feldstein VA, Norton ME, Wassel Fyr 179. ACOG Practice Bulletin #56: Multiple gesta-
C, Caughey AB, Machin GA. Unequal placental tion: complicated twin, triplet, and high-order
sharing and birth weight discordance in mono- multifetal pregnancy. Obstet Gynecol.
chorionic diamniotic twins. Am J Obstet 2004;104(4):869-883.
Gynecol. 2006;195(1):178-183.
180. O’Brien JE, Dvorin E, Yaron Y, et al. Differen-
171. Danskin FH, Neilson JP. Twin-to-twin transfu- tial increases in AFP, hCG, and uE3 in twin
sion syndrome: what are appropriate diagnostic pregnancies: impact on attempts to quantify
criteria? Am J Obstet Gynecol. 1989;161(2): Down syndrome screening calculations. Am J
365-369. Med Genet. 1997;73(2):109-112.

172. Reisner DP, Mahony BS, Petty CN, et al. Stuck 181. Melgar CA, Rosenfeld DL, Rawlinson K,
twin syndrome: outcome in thirty-seven consec- Greenberg M. Perinatal outcome after multifetal
utive cases. Am J Obstet Gynecol. reduction to twins compared with nonreduced
1993;169(4):991-995. multiple gestations. Obstet Gynecol.
1991;78(5:1):763-767.
173. Urig MA, Clewell WH, Elliott JP. Twin-twin
transfusion syndrome. Am J Obstet Gynecol. 182. Boulot P, Hedon B, Pelliccia G, Peray P, Laffar-
1990;163(5 Pt 1):1522-1526. gue F, Viala JL. Effects of selective reduction in
triplet gestation: a comparative study of 80 cases
174. Gonsoulin W, Moise KJ, Jr., Kirshon B, Cotton managed with or without this procedure. Fertil
DB, Wheeler JM, Carpenter RJ, Jr. Outcome of Steril. 1993;60(3):497-503.
twin-twin transfusion diagnosed before 28
weeks of gestation. Obstet Gynecol. 183. Smith-Levitin M, Kowalik A, Birnholz J, et al.
1990;75(2):214-216. Selective reduction of multifetal pregnancies to
twins improves outcome over nonreduced triplet
175. Ville Y, Hyett J, Hecher K, Nicolaides K. Prelim- gestations. Am J Obstet Gynecol.
inary experience with endoscopic laser surgery 1996;175(4:1):878-882.
for severe twin-twin transfusion syndrome. N
Engl J Med. 1995;332(4):224-227. 184. Evans MI, Dommergues M, Timor-Tritsch I, et
al. Transabdominal versus transcervical and
176. Elliott JP, Urig MA, Clewell WH. Aggressive transvaginal multifetal pregnancy reduction:
therapeutic amniocentesis for treatment of twin- international collaborative experience of more
twin transfusion syndrome. Obstet Gynecol. than one thousand cases. Am J Obstet Gynecol.
1991;77(4):537-540. 1994;170(3):902-909.

177. Wittmann BK, Farquharson DF, Thomas WD, 185. Evans MI, May M, Drugan A, Fletcher JC,
Baldwin VJ, Wadsworth LD. The role of feticide Johnson MP, Sokol RJ. Selective termination:
in the management of severe twin transfusion clinical experience and residual risks. Am J
syndrome. Am J Obstet Gynecol. Obstet Gynecol. 1990;162(6):1568-1572; dis-
1986;155(5):1023-1026. cussion 72-75.

178. Senat MV, Deprest J, Boulvain M, Paupe A, 186. Malone FD, Craigo SD, Chelmow D, D’Alton
Winer N, Ville Y. Endoscopic laser surgery ver- ME. Outcome of twin gestations complicated by
sus serial amnioreduction for severe twin-to- a single anomalous fetus. Obstet Gynecol.
twin transfusion syndrome. N Engl J Med. 1996;88(1):1-5.
2004;351(2):136-144.

CHAPTER 9: OBSTETRIC COMPLICATIONS 251


187. Evans MI, Goldberg JD, Dommergues M, et al. 196. Davison L, Easterling TR, Jackson JC,
Efficacy of second-trimester selective termina- Benedetti TJ. Breech extraction of low-birth-
tion for fetal abnormalities: international collab- weight second twins: can cesarean section be
orative experience among the world’s largest justified? Am J Obstet Gynecol.
centers. Am J Obstet Gynecol. 1994;171(1): 1992;166(2):497-502.
90-94.
197. Dommergues M, Mahieu-Caputo D, Mandel-
188. Wald N, Cuckle H, Wu TS, George L. Maternal brot L, Huon C, Moriette G, Dumez Y. Deliv-
serum unconjugated oestriol and human chori- ery of uncomplicated triplet pregnancies: is the
onic gonadotrophin levels in twin pregnancies: vaginal route safer? A case-control study. Am J
implications for screening for Down’s syn- Obstet Gynecol. 1995;172(2:1):513-517.
drome. Br J Obstet Gynaecol. 1991;98(9):
905-908. Preterm Premature Rupture of Membranes

189. Neveux LM, Palomaki GE, Knight GJ, Haddow 198. Capeless EL, Mead PB. Management of
JE. Multiple marker screening for Down syn- preterm premature rupture of membranes: lack
drome in twin pregnancies. Prenat Diagn. of a national consensus. Am J Obstet Gynecol.
1996;16(1):29-34. 1987;157(1):11-12.

190. Tabor A, Philip J, Madsen M, Bang J, Obel EB, 199. Bengtson JM, VanMarter LJ, Barss VA, Greene
Norgaard-Pedersen B. Randomised controlled MF, Tuomala RE, Epstein MF. Pregnancy out-
trial of genetic amniocentesis in 4606 low-risk come after premature rupture of the membranes
women. Lancet. 1986;1(8493):1287-1293. at or before 26 weeks gestation. Obstet Gynecol.
1989;73(6):921-927.
191. Hook EB, Cross PK, Schreinemachers DM.
Chromosomal abnormality rates at amniocente- 200. Park JS, Yoon BH, Romero R, et al. The rela-
sis and in live-born infants. JAMA. tionship between oligohydramnios and the
1983;249(15):2034-2038. onset of preterm labor in preterm premature rup-
ture of membranes. Am J Obstet Gynecol.
192. Rodis JF, Egan JF, Craffey A, Ciarleglio L, 2001;184(3):459-462.
Greenstein RM, Scorza WE. Calculated risk of
chromosomal abnormalities in twin gestations. 201. Bianco AT, Stone J, Lapinski R, Lockwood C,
Obstet Gynecol. 1990;76(6):1037-1041. Lynch L, Berkowitz RL. The clinical outcome
of preterm premature rupture of membranes in
193. Meyers C, Adam R, Dungan J, Prenger V. Ane- twin versus singleton pregnancies. Am J Perina-
uploidy in twin gestations: when is maternal tol. 1996;13(3):135-138.
age advanced? Obstet Gynecol.
1997;89(2):248-251. 202. Duff P, Huff RW, Gibbs RS. Management of
premature rupture of membranes and unfavor-
194. Strong TH, Jr., Phelan JP, Ahn MO, Sarno AP, able cervix in term pregnancy. Obstet Gynecol.
Jr. Vaginal birth after cesarean delivery in the 1984;63(5):697-702.
twin gestation. Am J Obstet Gynecol.
1989;161(1):29-32. 203. Hannah ME, Hodnett ED, Willan A, Foster GA,
Di Cecco R, Helewa M. Prelabor rupture of the
195. Gocke SE, Nageotte MP, Garite T, Towers CV, membranes at term: expectant management at
Dorcester W. Management of the nonvertex home or in hospital? The TermPROM Study
second twin: primary cesarean section, external Group. Obstet Gynecol. 2000;96(4):533-538.
version, or primary breech extraction. Am J
Obstet Gynecol. 1989;161(1):111-114.

252 OBSTETRICS AND GYNECOLOGY—2009


204. ACOG Practice Bulletin No. 80: premature rup- 213. Predanic M, Perni SC, Baergen RN, Jean-Pierre
ture of membranes. Clinical management C, Chasen ST, Chervenak FA. A sonographic
guidelines for obstetrician-gynecologists. assessment of different patterns of placenta pre-
Obstet Gynecol. 2007;109(4):1007-1019. via “migration” in the third trimester of preg-
nancy. J Ultrasound Med. 2005;24(6):773-780.
205. Vintzileos AM, Campbell WA, Nochimson DJ,
Weinbaum PJ. Preterm premature rupture of the 214. Gielchinsky Y, Mankuta D, Rojansky N, Laufer
membranes: a risk factor for the development of N, Gielchinsky I, Ezra Y. Perinatal outcome of
abruptio placentae. Am J Obstet Gynecol. pregnancies complicated by placenta accreta.
1987;156(5):1235-1238. Obstet Gynecol. 2004;104(3):527-530.

206. Ohlsson A. Treatments of preterm premature 215. Ananth CV, Smulian JC, Vintzileos AM. The
rupture of the membranes: a meta-analysis. Am association of placenta previa with history of
J Obstet Gynecol. 1989;160(4):890-906. cesarean delivery and abortion: a metaanalysis.
Am J Obstet Gynecol. 1997;177(5):1071-1078.
207. Wu YW, Colford JM, Jr. Chorioamnionitis as a
risk factor for cerebral palsy: A meta-analysis. 216. Oyelese Y, Smulian JC. Placenta previa, pla-
JAMA. 2000;284(11):1417-1424. centa accreta, and vasa previa. Obstet Gynecol.
2006;107(4):927-941.
208. Mercer BM, Arheart KL. Antimicrobial therapy
in expectant management of preterm premature 217. Wolf EJ, Mallozzi A, Rodis JF, Egan JF,
rupture of the membranes. Lancet. Vintzileos AM, Campbell WA. Placenta previa
1995;346(8985):1271-1279. is not an independent risk factor for a small for
gestational age infant. Obstet Gynecol.
209. Kenyon SL, Taylor DJ, Tarnow-Mordi W. 1991;77(5):707-709.
Broad-spectrum antibiotics for preterm,
prelabour rupture of fetal membranes: the 218. Zelop CC, Bromley B, Frigoletto FD, Jr.,
ORACLE I randomised trial. ORACLE Collab- Benacerraf BR. Second trimester sonographi-
orative Group. Lancet. 2001;357(9261):979- cally diagnosed placenta previa: prediction of
988. persistent previa at birth. Int J Gynaecol Obstet.
1994;44(3):207-210.
210. Ghidini A, Salafia CM, Kirn V, Doria V, Spong
CY. Biophysical profile in predicting acute 219. Ananth CV, Wilcox AJ. Placental abruption and
ascending infection in preterm rupture of mem- perinatal mortality in the United States. Am J
branes before 32 weeks. Obstet Gynecol. Epidemiol. 2001;153(4):332-337.
2000;96(2):201-206.
220. Ananth CV, Smulian JC, Demissie K, Vintzileos
AM, Knuppel RA. Placental abruption among
singleton and twin births in the United States:
Antepartum Hemorrhage

211. Sauer M, Parsons M, Sampson M. Placenta pre- risk factor profiles. Am J Epidemiol.
via: an analysis of three years’ experience. Am J 2001;153(8):771-778.
Perinatol. 1985;2(1):39-42.
221. Ananth CV, Berkowitz GS, Savitz DA, Lapinski
212. Bhide A, Prefumo F, Moore J, Hollis B, Thila- RH. Placental abruption and adverse perinatal
ganathan B. Placental edge to internal os dis- outcomes. JAMA. 1999;282(17):1646-1651.
tance in the late third trimester and mode of
delivery in placenta praevia. Bjog. 222. Oyelese KO, Turner M, Lees C, Campbell S.
2003;110(9):860-864. Vasa previa: an avoidable obstetric tragedy.
Obstet Gynecol Surv. 1999;54(2):138-145.

CHAPTER 9: OBSTETRIC COMPLICATIONS 253


11. Questions

1. A 27-year-old woman presents for her first prena- Regarding the management of preterm labor,
tal visit at 8 weeks gestation. She has a number of which of the following statements are true?
risk factors for cervical insufficiency. On review (More than 1 statement may be true.)
of her medical and obstetrical history, you con-
clude that she is a good candidate for elective cer- A. You should recommend strict bed rest and
vical cerclage. Which of the following elements of aggressive intravenous hydration as these
her history support this conclusion? interventions have been shown to prevent
preterm birth.
A. A history of in utero DES exposure.
B. You should start IV magnesium sulfate as
B. 3 prior first trimester elective pregnancy ter- this is the only drug approved by the FDA for
minations. the treatment of preterm labor.

C. A prior 20 week pregnancy loss C. You should start broad-spectrum antibiotic


characterized by painless cervical dilatation. therapy as this has been shown to prolong
latency.
D. A triplet pregnancy conceived through in
vitro fertilization. D. You should administer antenatal
corticosteroids.

2. A nulliparous woman presents at 18 weeks gesta-


tion complaining of a watery vaginal discharge. 4. A 28-year-old G4P3 is admitted to labor and
Sterile speculum examination reveals a cervix delivery at 29-3/7 weeks gestation with regular
which is 1-2 cm dilated and 80% effaced. After painful uterine contractions every 3 minutes.
reviewing the respective risks and benefits, the Bimanual examination shows her cervix to be
patient elects emergent cerclage placement over long and to admit a fingertip. Fetal heart rate
bed rest. At the time of cerclage placement, how- tracing is formally reactive with a baseline of
ever, you notice something which causes you to 130 bpm. A diagnosis of preterm contractions is
cancel the procedure. Which of the following clin- made. She has had 3 prior spontaneous preterm
ical findings would explain this change in plans? deliveries at 28-31 weeks gestation, and is very
concerned that this pregnancy will also end pre-
A. Evidence of uterine contractions. maturely. Which of the following statements
about screening for preterm labor are true?
B. Evidence of a vaginal yeast infection. (More than 1 statement may be true.)

C. Fetal membranes visible through the open


cervical os. A. Her history is highly predictive of preterm
birth. As such, no further screening tests are
D. A large cervical ectropion (cervical erosion). available.

B. A negative test for fetal fibronectin (fFN) in


3. A 36-year-old G7P1233 presents at 32-1/7 weeks cervicovaginal secretions is reassuring.
gestation complaining of increasing abdominal
pain and diminished fetal movement for 12 hours. C. Transvaginal sonography reveals a cervical
Bimanual examination shows her cervix to be 4 length of 3.6 cm. This finding should be
cm dilated and 90% effaced. Fetal cardiotocogra- viewed as reassuring.
phy shows evidence of uterine contractions every
three minutes. Fetal heart rate tracing is formally D. Given her increased risk of preterm birth, she
reactive, with a baseline of 140 bpm and no decel- is a good candidate for home uterine activity
erations. A diagnosis of preterm labor is made. monitoring.

254 OBSTETRICS AND GYNECOLOGY—2009


5. A 21-year-old G3P2 with two prior vaginal deliv- 7. A 36-year-old G6P2 calls the office complaining
eries is admitted to labor and delivery at 41-4/7 of no fetal movement for 8 hours. She is at 37
weeks gestation complaining of decreased fetal weeks gestation. On arrival, you confirm an
movement. Fetal cardiotocography shows the IUFD. Which of the following statements regard-
fetal heart rate to be formally reactive with a base- ing the management of IUFD at term are true?
line of 140 bpm, and the patient reports that she is (More than 1 statement may be true.)
again feeling fetal movements. Bimanual exami-
nation shows her cervix to be 1 cm dilated and A. It is highly likely that a cause for the IUFD
80% effaced. Estimated fetal weight is 4,400 g. As can be identified after delivery.
you are about to leave, she says: “My sister’s baby
died at 41 weeks. Why can’t you induce my labor B. Immediate induction of labor is indicated to
now, Doctor?” Which of the following statements prevent coagulopathy.
are true? (More than 1 statement may be true.)
C. Pathologic examination of the fetus and pla-
centa/fetal membranes is the single most use-
A. Induction of labor is appropriate, because her ful test to identify a cause for the IUFD.
pregnancy is post-term.
D. A Kleihauer-Betke test should be sent to
B. Induction of labor is appropriate to minimize identify fetomaternal hemorrhage.
maternal and fetal risks.

C. Induction of labor is appropriate for the indi- 8. An 18-year-old G1P0 presents for her first pre-
cation of impending macrosomia. natal visit. She is complaining of severe morn-
ing sickness. On examination, uterine size is
D. Induction of labor will not increase her risk greater than expected for gestational age. You
of cesarean delivery. perform an ultrasound examination and confirm
a monochorionic/monoamniotic twin gestation.
Which of the following complications of
6. A 43-year-old G1P0 presents to your office at 34- multiple gestations is specific to monochori-
5/7 weeks gestation complaining of a severe onic/monoamniotic pregnancies?
headache and flashing lights in front of her eyes.
Her supine BP is 140/90 and there is 3+ protein- A. Malpresentation.
uria. A diagnosis of preeclampsia is made. Which
of the following statements regarding the manage- B. Twin-to-twin transfusion syndrome.
ment of preeclampsia are true? (More than 1 state-
ment may be true.) C. Cord entanglement.

A. She should be delivered immediately by D. Preterm delivery.


cesarean for a diagnosis of moderate
preeclampsia.
9. A 27-year-old G3P1 with a strong family history of
B. You should measure her BP sitting and not multiple pregnancy presents for her first prenatal
lying. visit at 12 weeks gestation. Ultrasound examination
confirms a monochorionic/diamniotic twin preg-
C. You should start antihypertensive therapy in nancy. Which of the following statements regarding
an attempt to improve perinatal outcome. twin pregnancy are true?
(More than 1 statement may be true.)
D. Regional anesthesia is contraindicated.

CHAPTER 9: OBSTETRIC COMPLICATIONS 255


A. Monozygous twinning is not influenced by DES exposure remains controversial. Most clinicians
epidemiologic or genetic factors. believe that a history of in utero DES exposure alone
(without a history of prior pregnancy loss) is not an
B. 80% of twin pregnancies are dizygous. indication for prophylactic cerclage placement. Simi-
larly, elective cerclage has not been shown to be bene-
C. Perinatal mortality is higher with monozy- ficial in women with multiple pregnancies without a
gous than with dizygous twins. prior history of cervical insufficiency.

D. Perinatal mortality is highest with 2. A.


monochorionic/monoamniotic twins. The presence of uterine contractions suggests preterm
labor and not cervical insufficiency, and are an abso-
lute contraindication to cervical cerclage. Indeed, the
10. A 30-year-old G4P2 presents at 19 weeks gesta- presence of persistent uterine contractions requires the
tion with vaginal spotting. She has a history of 2 removal of any cerclage to avoid cervical laceration
prior cesarean deliveries. Ultrasound examination and/or uterine rupture. Although intra-amniotic infec-
reveals a low-lying placenta covering the cervical tion is an absolute contraindication to cerclage place-
os. Fetal well-being is confirmed. Which of the ment, vaginal yeast infection is not. Cervical ectro-
following statements regarding the management pion represents a physiologic extrusion of columnar
of placenta previa are true? (More than 1 state- epithelium out of the cervical canal under the influ-
ment may be true.) ence of steroid hormones, and should not interfere
with cervical cerclage placement. If the fetal mem-
A. There is a high probability that the placenta branes are found to be prolapsing through the external
will move away from the cervix as the preg- os at the time of cerclage placement, the risk of iatro-
nancy progresses. genic rupture of the fetal membranes may be as high
as 50%. Although this is not an absolute contraindica-
B. Given placenta previa and 2 prior cesarean tion to cerclage placement, the surgeon should pro-
deliveries, the likelihood of placenta acc- ceed with care. A number of techniques have been
reta is 25%. described in an attempt to reduce the fetal membranes
prior to cerclage placement, including Trendelenburg
C. Fetal nonstress testing is indicated after 32 position, back-filling the bladder, placement of a 30
weeks, because placenta previa is associated mL Foley catheter or moistened sponge forceps into
with uteroplacental insufficiency and IUGR. the cervical os, and/or therapeutic amniocentesis.

D. Pelvic examination should be deferred in all 3. D.


patients presenting with antepartum hemor- You should administer antenatal corticosteroids. A
rhage until placenta previa can be excluded. single course of antenatal corticosteroids decreases
the incidence of RDS, IVH, and (possibly) NEC by
50%, and is recommended for all pregnancies at high-
risk of delivering before 34 weeks gestation with
intact membranes and before 32 weeks with preterm
PROM. Maximal benefit is achieved 24-48 hours
Answers

1. C. after the initial dose. This effect lasts for 7 days, but it
A history suggestive of cervical insufficiency (ie, is unclear what happens thereafter. Repeated courses
acute, painless dilatation of the cervix usually in the of steroids are not generally recommended. Bed rest is
mid-trimester culminating in prolase and/or PROM recommended in up to 20% of all pregnancies, with an
with resultant preterm and often previable delivery) is estimated cost of >$250 million per year in the United
the only proven indication for elective cervical cer- States alone. Despite these recommendations, there is
clage. If the prior preterm delivery was the result of no proven benefit to bed rest in women at risk for
preterm labor and not cervical insufficiency, cerclage preterm labor. Intravenous hydration is also com-
placement is not indicated. Prophylactic cerclage for monly recommended in the acute setting, but without

256 OBSTETRICS AND GYNECOLOGY—2009


proven benefit. Broad-spectrum antibiotic therapy has 2.) Home uterine activity monitoring (HUAM). An
been shown to delay preterm birth and prolong increase in uterine contractility is a prerequisite for
latency in the setting of preterm PROM < 34 weeks. preterm labor. However, use of HUAM in women
However, there is no consistent evidence of prolonged at high risk does not reduce the incidence of
latency in the setting of preterm labor with intact preterm delivery, but does lead to over-diagnosis
membranes. As such, broad-spectrum antibiotics are of preterm labor, increased obstetric intervention,
not recommended for this indication. Pharmacologic and increased cost.
tocolytic therapy remains the cornerstone of modern
management. Although a number of alternative 3.) Assessment of cervical maturation. Serial digital
agents are now available for tocolysis, the only agent evaluation of the cervix is useful if the examina-
that is approved by the FDA for the treatment of tion remains normal. However, an abnormal cervi-
preterm labor is ritodrine hydrochloride (which has cal finding (shortening and/or dilatation) is associ-
been off formulary in North America for over 10 ated with preterm delivery in only 4% of low-risk
years, because it is too dangerous to administer in women and 12%-20% of high-risk women. Sono-
pregnancy). Although the ultimate goal of tocolysis is graphic evaluation of the cervix has demonstrated
to delay delivery to term, there is no reliable data to a strong inverse correlation between cervical
suggest that any tocolytic agents are able to delay length and preterm delivery. If the cervical length
delivery for longer than 24-48 hours. As such, the is below the 10th percentile for gestational age, the
most realistic goal of tocolysis is to delay delivery for pregnancy is at a six-fold increased risk of deliv-
48 hours to allow administration of antenatal corticos- ery prior to 35 weeks gestation.
teroids. No single tocolytic agent has a clear therapeu-
tic advantage. As such, the side effect profile of each 4.) Biochemical markers. Although a number of bio-
of the drugs will often determine which to use in a chemical markers have been associated with
given clinical setting. Magnesium sulfate (which acts preterm delivery, only fetal fibronectin (fFN) is
both to suppress nerve transmission to uterine smooth established as a screening test for preterm deliv-
muscle and to lower the concentration of intracellular ery. Elevated levels of fFN in cervicovaginal
calcium within myometrial cells, which is necessary secretions at 22-34 weeks gestation are associated
for activation of the myosinactin contractile unit) has with premature delivery. The real value of this test
traditionally been regarded as the first-line tocolytic lies in its negative predictive value (99% of
agent for use in preterm labor. More recent data sug- patients with a negative fFN test will not deliver
gests that nifedipine (a calcium channel blocker) is within 7 days).
equally effective and safer, and can be administered
orally. In Europe, the first-line tocolytic agent is atosi- 5.) Endocrine markers. The detection of elevated lev-
ban, an oxytocin receptor antagonist. els of estriol in maternal saliva (≥2.1 ng/mL) is
predictive of delivery prior to 37 weeks gestation
4. B. and C. in a high-risk population with a sensitivity of 68%-
It is clear from this patient’s history that she is at high 87%, a specificity of 77% and a false positive rate
risk of preterm delivery. The screening tests currently of 23%. Serial (weekly) measurments may be
available for prediction of preterm birth fall into 5 more accurate in predicting pretermbirth than a
broad categories: single measurement. This test is not currently
available in the United States.
1.) Risk factor scoring. A number of risk factors for
preterm labor have been identified. However, 5. B. and D.
reliance on risk factors alone will fail to identify Post-term (prolonged) pregnancy refers to a preg-
over 50% of pregnancies which deliver preterm, nancy that has extended to or beyond a gestational age
and most women designated at risk will deliver at of 42.0 weeks (294 days) from the first day of the last
term. menstrual period. As such, this patient’s pregnancy is
currently at term, not post-term. Clearly, accurate
pregnancy dating is critical to the diagnosis. Post-term
pregnancy is associated with both fetal and maternal

CHAPTER 9: OBSTETRIC COMPLICATIONS 257


risks. Perinatal mortality (stillbirths plus early neona- preeclampsia (in the absence of thrombocytopenia)
tal deaths) at ≥ 42 weeks of gestation is twice that at with close attention to volume expansion and anes-
term and increases 4-fold at 43 weeks and 5- to 7-fold thetic technique. The use of antihypertensive agents to
at 44 weeks. Chronic uteroplacental insufficiency, control mildly elevated BP in the setting of
asphyxia and intrauterine infection all contribute to preeclampsia has not been shown to alter the course of
the excess perinatal deaths. Post-term infants are the disease nor to diminish perinatal morbidity or
larger than term infants, with a higher incidence of mortality, and may indeed reduce uteroplacental per-
macrosomia (defined as a sonographic EFW >4500 fusion. Moreover, the use of such agents may serve to
g). Complications associated with fetal macrosomia remove the most sensitive index of worsening
include prolonged labor, cephalopelvic disproportion, preeclampsia. For these reasons, antihypertensive
and shoulder dystocia with resultant risks of orthope- therapy is not recommended for mild-to-moderate
dic or neurologic injury. Post-term pregnancies are at hypertension in the setting of preeclampsia.
increased risk of umbilical cord compression from
oligohydramnios, nonreassuring fetal antepartum or 7. C. and D.
intrapartum assessment, meconium aspiration, short- Causes of unexplained IUFD at term can be identified
term neonatal complications (hypoglycemia, in only around 50% of cases. Pathologic examination
seizures) and long-term neurologic sequelae. For of the fetus and placenta/fetal membranes is the single
these reasons, there does appear to be a small advan- most useful test to identify a cause for the IUFD. Fetal
tage to routine induction of labor at 41 weeks gesta- karyotyping should be considered in all cases of fetal
tion, regardless of parity or method of induction. death to identify chromosomal abnormalities, particu-
However, induction of labor for the indication of larly in cases with documented fetal structural abnor-
“impending macrosomia” is not appropriate, and such malities. Fetal-maternal hemorrhage occurs in all
an approach has not been shown to decrease cesarean pregnancies, but is usually minimal. In rare instances,
delivery rates or improve perinatal outcome. Routine fetal-maternal hemorrhage may be massive, leading
induction of labor at 41 weeks will not increase the to fetal demise. The Kleihauer-Betke (acid elution)
cesarean rate for multipara and nullipara with a favor- test allows an estimate of the volume of fetal blood in
able cervical exam (although the cesarean delivery the maternal circulation and should be sent as soon as
rate of primipara with an unfavorable cervical exam is possible since fetal cells are very rapidly cleared from
likely to be increased). the maternal circulation. Intra-amniotic infection
resulting in fetal death is usually evident on clinical
6. B. exam. Placental culture and histologic examination of
Preeclampsia is a clinical diagnosis encompassing 3 the fetus, placenta/fetal membranes, and umbilical
elements: 1.) new-onset hypertension (defined as a cord may be useful. Immediate delivery is not neces-
sustained BP ≥140/90 in a previously normotensive sary. Overall, >90% of women will go into labor
woman); 2.) new-onset proteinuria (>300 mg/24 h or within 2 weeks of fetal death. Around 20%-25% of
≥2+ on a clean-catch urinalysis in the absence of uri- women that retain a dead singleton fetus for longer
nary infection); and 3.) non-dependent edema than 3 weeks will develop disseminated intravascular
(although this is not a prerequisite for diagnosis). BP coagulopathy (DIC) due to excessive consumption of
should always be measured in the sitting position clotting factors. Therefore, delivery should be
using the 5th Korotkoff sound (disappearance of pul- effected within this time period.
sation) to describe the diastolic BP. Preeclampsia is
classified as either “mild” or “severe” (there is no 8. C.
moderate preeclampsia). This patient has severe Multiple pregnancy should be suspected in women at
preeclampsia by symptoms (headache, visual high risk, excessive symptoms of pregnancy or uter-
changes) and should be delivered immediately. How- ine size larger than expected. Overall, antepartum
ever, immediate delivery need not necessarily mean complications develop in 80% of multiple pregnan-
cesarean delivery. Cervical ripening agents may be cies as compared with around 30% of singleton gesta-
used if the cervix is not favorable prior to induction, tions. Preterm delivery is the most common complica-
but prolonged inductions should be avoided. Regional tion, and the risk of preterm delivery increases as fetal
analgesia can be safely administered in the setting of number increases. Malpresentation is a common com-

258 OBSTETRICS AND GYNECOLOGY—2009


plication of multiple pregnancies. Cord entanglement, perinatal mortality, which is especially high with
on the other hand, is specific to monochori- monochorionic/monoamniotic twins (65%-70%).
onic/monoamniotic pregnancies. Overall, it is a rare Chorionicity is determined most accurately by exami-
complication (1 in 25,000 births), but may occur in up nation of the membranes after delivery. Antenatal
to 70% of monochorionic/monoamniotic pregnancies diagnosis is more difficult. Identification of separate
and is thought to account for >50% of perinatal mor- sex fetuses or two separate placentae confirms
tality in this subgroup. Twin polyhydram- dichorionic/diamniotic placentation.
nios/oligohydramnios sequence results from an
imbalance in blood flow from the “donor” twin to the 10. A. and D.
“recipient.” Both twins are at risk for adverse events. Placenta previa refers to implantation of the placenta
Twin-to-twin transfusion is a subset of poly/oligo over the cervical os in advance of the fetal presenting
sequence seen in 15% of monochorionic pregnancies, part. In any patient presenting with antepartum hem-
and is due to unbalanced vascular communications orrhage, pelvic and/or rectal examinations should be
between the fetal circulations. Overall perinatal mor- avoided until placenta previa is excluded. Placenta
tality is 40%-80%. Treatment options include expec- previa is primarily a sonographic diagnosis. Placenta
tant management, serial amniocentesis, indomethacin previa may resolve with time, thereby permitting
(to decrease fetal urine output), laser obliteration of vaginal delivery. Indeed, only 5% of low-lying pla-
the placental vascular communications or selective centae identified by ultrasound at 14-20 weeks gesta-
fetal reduction. tion persist to term. Maternal complications include
placenta accreta, which refers to abnormal attachment
9. All are correct. of placental villi to the uterine wall. In the absence of
Of pregnancies with placenta previa, 25% with previa placenta previa, placenta accreta is rare. However, it
and 1 prior cesarean, and 60% with previa and 2 or complicates 5%-15% of pregnancies with placenta
more prior cesareans. Neonatal complications include previa, 25% with previa and 1 prior cesarean, and
preterm birth and malpresentation. However, placenta 60% with previa and 2 or more prior cesareans.
previa is not associated with IUGR. Elective cesarean Neonatal complications include preterm birth and
delivery is generally recommended at 36-37 weeks malpresentation. However, placenta previa is not
gestation. 80% of twin pregnancies are dizygous associated with IUGR. Elective cesarean delivery is
(derived from 2 separate embryos). Dizygous twin- generally recommended at 36-37 weeks gestation.
ning is influenced by a number of epidemiologic fac-
tors, including a family or personal history of multiple
pregnancy, advanced maternal age, multiparity,
African American, and ART. Monozygous twinning,
on the other hand, is a random event that occurs in
around 1 in 300 pregnancies (although the risk may be
increased 2- to 3-fold with in vitro fertilization). Peri-
natal mortality is higher with monozygous(30%-
50%) than with dizygous twins (10%-20%). Chorion-
icity refers to the arrangement of membranes in multi-
ple pregnancies. In monozygous twinning, the timing
of the cell division determines the chorionicity. If the
zygote divides within 3 days of fertilization, the result
is dichorionic/diamniotic placentation (30% of all
monozygous pregnancies); if the division occurs
between day 3 and day 8, the result is a monochori-
onic/diamniotic pregnancy (65%); between day 8 and
day 13, a monochorionic/ monoamniotic pregnancy
ensues (<5%); and if the division occurs on or after
day 13, incomplete separation (conjoined twins) is the
rule (<0.5%). Chorionicity correlates directly with

CHAPTER 9: OBSTETRIC COMPLICATIONS 259


260 OBSTETRICS AND GYNECOLOGY—2009